[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 907
1. Di Tommaso L, Kuhn E, Kurrer M, Zettl A, Marx A, Müller-Hermelink HK, Roncalli M, Rosai J: Thymic tumor with adenoid cystic carcinomalike features: a clinicopathologic study of 4 cases. Am J Surg Pathol; 2007 Aug;31(8):1161-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymic tumor with adenoid cystic carcinomalike features: a clinicopathologic study of 4 cases.
  • Thymic carcinomas are rare malignant neoplasms which comprise several histologic subtypes.
  • Adenoid cystic carcinoma (ACC) is included among these subtypes even if it has never been formally reported.
  • We evaluated the clinical, radiologic, morphologic, immunohistochemical, and genetic features of 4 cases of thymic neoplasms with ACC-like features retrieved from the authors' consult files.
  • The clinical history (no evidence of ACC in other sites), radiologic findings (a mass in the thymic region), and morphologic features (residual thymic tissue at the periphery of the neoplasm) strongly supported their primary thymic nature.
  • We have interpreted them as a microscopic subtype of well-differentiated thymic carcinoma of low-grade malignancy, an impression supported by the admittedly limited follow-up information.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Thymus Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667537.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


2. Crain N, Nelson BL, Barnes EL, Thompson LD: Ceruminous gland carcinomas: a clinicopathologic and immunophenotypic study of 17 cases. Head Neck Pathol; 2009 Mar;3(1):1-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ceruminous gland carcinomas: a clinicopathologic and immunophenotypic study of 17 cases.
  • BACKGROUND: Ceruminal gland carcinomas are rare neoplasms confined to the skin lining the cartilaginous part of the external auditory canal.
  • Histologically, the tumors demonstrated a solid to cystic pattern, composed of an infiltrating glandular to cribriform arrangement of epithelial cells.
  • Tumors were divided into three types of adenocarcinoma based on pattern of growth and cell type (ceruminous, NOS [n = 12], adenoid cystic [n = 4], mucoepidermoid [n = 1]).
  • CK7 and CD117 highlighted the luminal cells, while S1-00 protein showed a predilection for the basal cells of ceruminous and adenoid cystic carcinomas.
  • Metastatic adenocarcinoma or direct extension from salivary gland neoplasms are the principle differential considerations.
  • Eleven patients were alive or had died of unrelated causes without evidence of disease (mean, 11.2 years); six patients had died with disease (mean, 4.9 years), all of whom had developed local recurrence.
  • CONCLUSION: Ceruminous-type carcinomas, with the exception of ceruminous mucoepidermoid carcinoma, all demonstrated a dual cell population of basal myoepithelial-type cells and luminal apocrine cells.
  • The specific histologic sub-type does not influence the long-term patient outcome.
  • [MeSH-major] Carcinoma / pathology. Ear Neoplasms / pathology. Ear, External / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Middle Aged. Otorhinolaryngologic Surgical Procedures. Radiotherapy. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 1973 Jun;65(6):909-13 [4350087.001]
  • [Cites] J Laryngol Otol. 1973 Dec;87(12):1201-10 [4357381.001]
  • [Cites] J Laryngol Otol. 1974 Apr;88(4):363-8 [4824672.001]
  • [Cites] Can J Otolaryngol. 1974;3(2):194-201 [4831936.001]
  • [Cites] Arch Otolaryngol. 1974 Nov;100(5):395-7 [4429488.001]
  • [Cites] Cancer. 1975 Sep;36(3):1072-6 [171051.001]
  • [Cites] J Laryngol Otol. 1975 Jul;89(7):707-20 [171328.001]
  • [Cites] Arch Otolaryngol. 1975 Nov;101(11):702-5 [1200915.001]
  • [Cites] Laryngoscope. 1977 Oct;87(10 Pt 1):1601-12 [198620.001]
  • [Cites] J Can Assoc Radiol. 1977 Dec;28(4):287-90 [303644.001]
  • [Cites] Cancer. 1978 Feb;41(2):545-53 [630537.001]
  • [Cites] Arch Otolaryngol. 1980 Jan;106(1):13-9 [6243462.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1990 Sep;99(9 Pt 1):714-21 [2396807.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Dec;30(13):1034-7 [1714051.001]
  • [Cites] Otolaryngol Head Neck Surg. 1992 Feb;106(2):214-5 [1310808.001]
  • [Cites] Acta Morphol Hung. 1991;39(2):157-65 [1789146.001]
  • [Cites] J Laryngol Otol. 1992 Aug;106(8):727-32 [1328435.001]
  • [Cites] Pathology. 1992 Oct;24(4):315-9 [1337771.001]
  • [Cites] Rev Laryngol Otol Rhinol (Bord). 1993;114(1):49-52 [8191051.001]
  • [Cites] J Laryngol Otol. 1994 Aug;108(8):706-9 [7930929.001]
  • [Cites] Cancer. 1982 Dec 15;50(12):2873-83 [6291744.001]
  • [Cites] J Laryngol Otol. 1995 Mar;109(3):180-8 [7745330.001]
  • [Cites] Am J Dermatopathol. 1995 Apr;17(2):169-73 [8600783.001]
  • [Cites] J Laryngol Otol. 1996 Mar;110(3):249-51 [8730361.001]
  • [Cites] J Am Anim Hosp Assoc. 1996 Sep-Oct;32(5):448-52 [8875362.001]
  • [Cites] Indian J Cancer. 1997 Sep;34(3):139-42 [9491676.001]
  • [Cites] Br J Plast Surg. 1998 Jun;51(4):317-20 [9771352.001]
  • [Cites] J Laryngol Otol. 1957 Dec;71(12):824-31 [13491925.001]
  • [Cites] J Laryngol Otol. 1957 Dec;71(12):832-7 [13491926.001]
  • [Cites] Cancer. 1964 Jan;17:67-75 [14102073.001]
  • [Cites] J Otolaryngol. 1980 Dec;9(6):482-6 [6162967.001]
  • [Cites] J Laryngol Otol. 1981 Aug;95(8):843-8 [6267150.001]
  • [Cites] J Neurosurg. 1981 Dec;55(6):952-6 [7299469.001]
  • [Cites] Am J Clin Pathol. 1982 Feb;77(2):153-61 [7039299.001]
  • [Cites] Laryngoscope. 1983 Mar;93(3):326-40 [6300574.001]
  • [Cites] Hiroshima J Med Sci. 1984 Mar;33(1):17-22 [6090347.001]
  • [Cites] J Am Acad Dermatol. 1984 Nov;11(5 Pt 1):841-7 [6096419.001]
  • [Cites] Laryngoscope. 1987 Feb;97(2):158-64 [3807618.001]
  • [Cites] Am J Otol. 1987 Nov;8(6):485-8 [3434612.001]
  • [Cites] Cancer. 1989 Dec 1;64(11):2292-302 [2804921.001]
  • [Cites] J R Soc Med. 1990 Jan;83(1):34-7 [2406442.001]
  • [Cites] J Laryngol Otol. 1999 Jun;113(6):578-80 [10605594.001]
  • [Cites] J Otolaryngol. 2001 Dec;30(6):373-7 [11771014.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jan;126(1):87-9 [11800656.001]
  • [Cites] J Oral Maxillofac Surg. 2002 Apr;60(4):465-9 [11928113.001]
  • [Cites] Mod Pathol. 2002 May;15(5):543-55 [12011260.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):834-7 [12117346.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2002 Sep-Oct;64(5):358-63 [12417781.001]
  • [Cites] J Laryngol Otol. 2003 Mar;117(3):202-4 [12648377.001]
  • [Cites] Am J Otolaryngol. 2003 Jul-Aug;24(4):274-7 [12884224.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2004 Dec;24(6):354-6 [15952686.001]
  • [Cites] Ear Nose Throat J. 2005 Sep;84(9):560-1 [16261754.001]
  • [Cites] Otol Neurotol. 2006 Jan;27(1):97-101 [16371854.001]
  • [Cites] Indian J Pathol Microbiol. 2006 Oct;49(4):587-9 [17183866.001]
  • [Cites] Acta Otolaryngol. 2007 Mar;127(3):280-4 [17364365.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Dec;137(6):893-8 [18036417.001]
  • [Cites] J Neurosurg. 2008 Jan;108(1):97-104 [18173317.001]
  • [Cites] B-ENT. 2007;3(4):195-9 [18265725.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2008 Jun;134(6):663-6 [18559737.001]
  • [Cites] Laryngoscope. 2008 Sep;118(9):1591-6 [18677277.001]
  • [Cites] Auris Nasus Larynx. 2003 Aug;30(3):287-90 [12927294.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):792-4 [14526681.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Sep-Oct;65(5):300-2 [14730188.001]
  • [Cites] J Laryngol Otol. 2003 Dec;117(12):951-4 [14738604.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):308-18 [15104293.001]
  • [Cites] Arch Otolaryngol. 1967 Jul;86(1):66-9 [6026961.001]
  • [Cites] Arch Dermatol. 1968 Oct;98(4):344-8 [4300211.001]
  • [Cites] Arch Otolaryngol. 1970 Jul;92(1):40-2 [4192890.001]
  • [Cites] J Laryngol Otol. 1970 Jul;84(7):743-5 [5432829.001]
  • [Cites] Pract Otorhinolaryngol (Basel). 1970;32(4):211-8 [5477506.001]
  • [Cites] Cancer. 1971 Sep;28(3):775-80 [4328926.001]
  • [Cites] Tex Med. 1970 Oct;66(10):56-9 [4335213.001]
  • [Cites] Cancer. 1972 May;29(5):1169-78 [5021609.001]
  • (PMID = 20596983.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2807538
  • [Keywords] NOTNLM ; Adenoid cystic / Carcinoma / Ceruminal / Ceruminous / Ear / Gland / Immunohistochemistry / Mucoepidermoid / Prognosis
  •  go-up   go-down


3. Cernea CR, Dias FL, Lima RA, Farias T, Mendonça UB, Vellutini E, Gomes MQ, Nogueira J, Lorencetti RR, Brandão LG, Dos Santos LR, Morais-Besteiro J, Ishida LC, Galvão MS: Atypical facial access: an unusually high prevalence of use among patients with skull base tumors treated at 2 centers. Arch Otolaryngol Head Neck Surg; 2007 Aug;133(8):816-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To analyze the influence of the unique percentage of skin carcinomas with skull base invasion on the choice of the facial surgical approach.
  • Data were collected on demographic distribution, location of the primary tumor, histologic type, type of operation, reconstruction, complications, and outcome.
  • The initial location of the tumor was the craniofacial skin in 63.5% of cases, ethmoid in 10.8%, maxilla in 2.3%, orbit in 1.9%, and other origins, including endocranial, in 19.4%.
  • The histologic type of the lesions was basal cell carcinoma in 42.0% of cases, squamous cell carcinoma in 29.5%, esthesioneuroblastoma in 5.3%, adenocarcinoma in 3.9%, adenoid cystic carcinoma in 2.8%, and other types in 16.5%.
  • Owing to this high prevalence of advanced skin carcinomas, the most commonly employed facial approach was atypical, tailored to encompass all compromised skin and underlying tissues, in 55.5% of cases, followed by the Weber-Ferguson approach, with all its variations (eg, nasal swing) in 17.8%, lateral rhinotomy in 12.2%, facial translocation in 3.8%, and other facial techniques in 7.7%.
  • CONCLUSION: In most situations, head and neck surgeons chose an atypical surgical approach to properly resect all facial structures invaded by very advanced skin cancers.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Face / surgery. Neurosurgical Procedures / methods. Reconstructive Surgical Procedures / methods. Skin Neoplasms / surgery. Skull Base Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17709623.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Wu H, Huang Q, Wang ZY, Cao RP, Zhang ZH: [Surgery of jugular foramen region tumors]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2006 Sep;41(9):665-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mastoid and neck approach, the infratemporal fossa approach with and without rerouting the facial nerve, the combined transcochlear and infratemporal fossa approach were respectively used according to the tumor type, size, auditory, facial and lower cranial nerve functions.
  • RESULTS: In this series of 32 patients, 13 were paragangliomas, 10 schwannomas,2 meningiomas, 2 giant cell tumors, 1 chondrosarcoma, 1 mucochondrosarcoma, 1 adenoid cystic carcinoma, 1 rhabdomyosarcoma and 1 case cholesterol Granuloma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17111806.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


5. Andreadis D, Epivatianos A, Mireas G, Nomikos A, Poulopoulos A, Yiotakis J, Barbatis C: Immunohistochemical detection of E-cadherin in certain types of salivary gland tumours. J Laryngol Otol; 2006 Apr;120(4):298-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reduction and/or absence of E-cadherin was only observed in pleomorphic adenoma at the peripheral cells of the duct-like or island structures, or in the cells exhibiting plasmacytoid or stromal differentiation.
  • Furthermore, a weak to moderate loss of expression which was related to tissue tumour subtype was seen in malignant tumours such as: adenoid cystic carcinomas; polymorphous low-grade adenocarcinomas; acinic cell carcinomas; and mucoepidermoid low-grade, epithelial-myoepithelial, lymphoepithelial and squamous low-grade carcinomas.
  • Moderate to extreme loss or alternative cytoplasmic non-functional expression were observed in cases of salivary ductal carcinoma, carcinosarcoma, myoepithelial carcinoma, oncocytic adenocarcinoma, unspecified adenocarcinoma and squamous high-grade carcinomas.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Cadherins / analysis. Carcinoma, Adenoid Cystic / chemistry. Carcinoma, Ductal / chemistry. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adenolymphoma / chemistry. Adenoma / chemistry. Adenoma, Pleomorphic / chemistry. Humans. Immunohistochemistry / methods. Salivary Gland Diseases / metabolism. Salivary Glands / chemistry

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16623973.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins
  •  go-up   go-down


6. Gaissert HA, Grillo HC, Shadmehr BM, Wright CD, Gokhale M, Wain JC, Mathisen DJ: Laryngotracheoplastic resection for primary tumors of the proximal airway. J Thorac Cardiovasc Surg; 2005 May;129(5):1006-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Twenty-five patients aged 15 to 77 years presented with adenoid cystic carcinomas (n = 9), squamous cell carcinomas (n = 6), and other airway tumors (n = 10).
  • Four (16%) patients died of disease.
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / surgery. Carcinoma, Squamous Cell / surgery. Chondrosarcoma / surgery. Cough / etiology. Deglutition Disorders / etiology. Dyspnea / etiology. Hemoptysis / etiology. Hoarseness / etiology. Humans. Massachusetts / epidemiology. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / etiology. Pain / etiology. Respiratory Sounds / etiology. Retrospective Studies. Sarcoma / surgery. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867773.001).
  • [ISSN] 0022-5223
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Teymoortash A, Pientka A, Schrader C, Tiemann M, Werner JA: Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis. J Cancer Res Clin Oncol; 2006 Jan;132(1):51-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis.
  • PURPOSE: Adenoid cystic carcinoma (ACC) is one of the most common malignant tumours of the salivary glands characterized by multiple recurrences and distant metastasis resulting in significantly worsening prognosis.
  • There was no statistical significance in the correlation of galectin-3 expression and disease-free survival and overall survival rate (P=0.095 and 0.102, respectively).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / chemistry. Carcinoma, Adenoid Cystic / pathology. Galectin 3 / analysis. Head and Neck Neoplasms / chemistry. Head and Neck Neoplasms / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1996 May;179(1):43-8 [8691344.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2570-5 [12171885.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1193-7 [14623749.001]
  • [Cites] Glycoconj J. 2004;19(7-9):543-9 [14758078.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):815-22 [7677193.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 Jun;120(6):834-40 [10352436.001]
  • [Cites] Glycoconj J. 2004;19(7-9):527-35 [14758076.001]
  • [Cites] Laryngoscope. 2004 Jul;114(7):1194-9 [15235347.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Jul;120(7):721-6 [8018324.001]
  • [Cites] Arch Otolaryngol. 1974 Aug;100(2):81-90 [4367208.001]
  • [Cites] Oral Oncol. 1997 Jul;33(4):275-8 [9307718.001]
  • [Cites] Head Neck. 2002 Aug;24(8):779-83 [12203804.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1986 Aug;11(4):267-91 [3028679.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2004 Apr;12(2):127-32 [15167050.001]
  • [Cites] Int J Oral Maxillofac Surg. 1997 Dec;26(6):435-9 [9418145.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2001 Jul-Aug;63(4):233-42 [11408820.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Feb;125(2):149-52 [10037280.001]
  • [Cites] Am J Surg. 1974 Oct;128(4):512-20 [4371368.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1389-93 [10778968.001]
  • [Cites] Am J Surg. 1997 Nov;174(5):495-8 [9374223.001]
  • [Cites] Ann Surg Oncol. 1999 Sep;6(6):572-8 [10493626.001]
  • [Cites] Cancer. 1978 Jul;42(1):265-82 [208752.001]
  • [Cites] Int J Cancer. 1994 Feb 15;56(4):474-80 [8112883.001]
  • [Cites] Ann Oncol. 1993 Nov;4(9):785-8 [8280659.001]
  • [Cites] Am J Surg. 1992 Dec;164(6):623-8 [1334380.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Oct;88(4):473-8 [10519758.001]
  • [Cites] Cancer. 1986 Feb 1;57(3):519-24 [3002583.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):687-91 [12118104.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):867-9 [8922205.001]
  • [Cites] Int J Oncol. 2000 Aug;17(2):271-6 [10891535.001]
  • [Cites] Prostate. 2000 Jul 1;44(2):118-23 [10881021.001]
  • (PMID = 16184379.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3
  •  go-up   go-down


8. Keikhaee MR, Kudo Y, Siriwardena S, Wu L, Ogawa I, Takata T: Skp2 expression is associated with down-regulation of p27 protein and cell proliferation in salivary adenoid cystic carcinoma. Virchows Arch; 2007 May;450(5):567-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skp2 expression is associated with down-regulation of p27 protein and cell proliferation in salivary adenoid cystic carcinoma.
  • Adenoid cystic carcinoma (ACC) is a malignant salivary gland tumor, which shows frequent recurrence and metastasis, ultimately with a poor outcome.
  • In this study, we transfected nondegradable p27 mutant (T187A) and wild-type gene into ACC cell line.
  • These findings, overall, suggest that Skp2 may play an important role in ACC development through the down-regulation of p27 and that Skp2 siRNA can be a novel modality of cancer gene therapy for suppression of p27 down-regulation in ACC.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Cell Proliferation. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. S-Phase Kinase-Associated Proteins / metabolism. Salivary Gland Neoplasms / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1994 Jul 15;78(1):67-74 [8033213.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5043-8 [11309491.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 1980;42(6):346-367 [6256700.001]
  • [Cites] J Cell Physiol. 2000 Apr;183(1):10-7 [10699961.001]
  • [Cites] Oral Oncol. 2005 Feb;41(2):105-16 [15695111.001]
  • [Cites] Cancer. 2001 May 1;91(9):1745-51 [11335900.001]
  • [Cites] Nature. 1999 Mar 11;398(6723):160-5 [10086358.001]
  • [Cites] Blood. 2000 Jan 15;95(2):619-26 [10627471.001]
  • [Cites] N Engl J Med. 1982 Mar 25;306(12):718-22 [6278304.001]
  • [Cites] Nat Med. 1997 Feb;3(2):231-4 [9018245.001]
  • [Cites] Science. 1995 Aug 4;269(5224):682-5 [7624798.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1457-66 [11943729.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Jul;58(7):691-6 [10411338.001]
  • [Cites] JAMA. 1967 Feb 20;199(8):519-24 [4960081.001]
  • [Cites] Genes Dev. 1999 May 1;13(9):1181-9 [10323868.001]
  • [Cites] Int J Cancer. 2001 Jun 20;96(3):149-58 [11410883.001]
  • [Cites] Cell. 1994 Nov 18;79(4):573-82 [7954824.001]
  • [Cites] Head Neck. 2002 Aug;24(8):779-83 [12203804.001]
  • [Cites] Nat Cell Biol. 1999 Aug;1(4):193-9 [10559916.001]
  • [Cites] Cell. 1994 Nov 18;79(4):551-5 [7954821.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7044-7 [11585732.001]
  • [Cites] Curr Biol. 1999 Jun 17;9(12 ):661-4 [10375532.001]
  • [Cites] Cell. 1995 Sep 22;82(6):915-25 [7553852.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):207-16 [12107105.001]
  • [Cites] Arch Dermatol. 1987 Nov;123(11):1541a-1544a [2445299.001]
  • [Cites] Am J Surg. 1974 Oct;128(4):512-20 [4371368.001]
  • [Cites] Nat Cell Biol. 1999 Aug;1(4):207-14 [10559918.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1982;395(3):289-301 [6287713.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2515-20 [11226270.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1062-9 [6088017.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3819-25 [12097295.001]
  • [Cites] Arch Otolaryngol. 1983 Oct;109(10):662-8 [6311147.001]
  • [Cites] Cell. 1994 Jul 15;78(1):59-66 [8033212.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1259-63 [9102210.001]
  • [Cites] Oncology. 2002;63(4):398-404 [12417796.001]
  • [Cites] J Oral Pathol Med. 1995 Nov;24(10):437-42 [8600278.001]
  • [Cites] J Exp Med. 1987 Jun 1;165(6):1761-6 [3585251.001]
  • [Cites] J Clin Invest. 2002 Sep;110(5):633-41 [12208864.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):928-35 [10491517.001]
  • [Cites] Cancer. 1986 Jan 15;57(2):312-9 [3002581.001]
  • [Cites] Nat Cell Biol. 2004 Dec;6(12 ):1229-35 [15531880.001]
  • (PMID = 17431674.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proliferating Cell Nuclear Antigen; 0 / RNA, Small Interfering; 0 / S-Phase Kinase-Associated Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


9. Güerrissi JO, Quiroga JP: Adnexal carcinomas of the head and neck. Indian J Plast Surg; 2008 Jul;41(2):229-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adnexal carcinomas of the head and neck.
  • Adnexal carcinomas of the skin are rare and they derive from structures such as sweat glands, sebaceous glands, and hair follicles.
  • Adnexal tumors represent 1-2% of skin cancers.
  • Four (50%) of them had malignant cylindromas, two (25%) had sebaceous carcinoma, and the other two (25%) syringoid eccrine carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatologica. 1980;160(6):361-70 [6248388.001]
  • [Cites] Br J Plast Surg. 1990 Nov;43(6):702-5 [2175228.001]
  • [Cites] Int J Oral Maxillofac Surg. 1996 Jun;25(3):196-8 [8872222.001]
  • [Cites] Ann Plast Surg. 1996 Feb;36(2):194-6 [8919387.001]
  • [Cites] Semin Cutan Med Surg. 1999 Sep;18(3):233-43 [10468043.001]
  • [Cites] Histopathology. 1980 Jul;4(4):445-66 [6253380.001]
  • [Cites] Genet Couns. 2004;15(2):175-82 [15287417.001]
  • (PMID = 19753272.001).
  • [ISSN] 0970-0358
  • [Journal-full-title] Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India
  • [ISO-abbreviation] Indian J Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2740523
  • [Keywords] NOTNLM ; Adnexal carcinomas / adnexal tumors / skin cancer
  •  go-up   go-down


10. Santos RR, Damasceno RW, de Pontes FS, Cursino SR, Nishiwaki-Dantas MC, Vital Filho J, Dantas PE: Ten-year follow-up of a case series of primary epithelial neoplasms of the lacrimal gland: clinical features, surgical treatment and histopathological findings. Arq Bras Oftalmol; 2010 Jan-Feb;73(1):33-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ten-year follow-up of a case series of primary epithelial neoplasms of the lacrimal gland: clinical features, surgical treatment and histopathological findings.
  • PURPOSE: To describe and analyze the features of a cases series of patients with primary epithelial neoplasms of the lacrimal gland, its surgical treatment, and histopathological findings.
  • RESULTS: During the study period, there were 12 patients, 5 (41.7%) with benign tumors, all pleomorphic adenomas (benign mixed tumor) and 7 (58.3%) with malignant neoplasms, thus distributed: four cases of adenoid cystic carcinoma, two of mucoepidermoid carcinoma and one carcinoma expleomorphic adenoma.
  • Three patients developed distant metastasis and died of disease.
  • CONCLUSIONS: The most frequent primary epithelial neoplasms of the lacrimal gland were pleomorphic adenoma and adenoid cystic carcinoma during the study period.
  • The histopathological diagnosis and the disease initial stage can play a significant role in patient's survival.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / pathology. Lacrimal Apparatus / pathology. Lacrimal Apparatus Diseases / pathology

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20464111.001).
  • [ISSN] 1678-2925
  • [Journal-full-title] Arquivos brasileiros de oftalmologia
  • [ISO-abbreviation] Arq Bras Oftalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


11. Freier K, Flechtenmacher C, Walch A, Ohl S, Devens F, Burke B, Hassfeld S, Lichter P, Joos S, Hofele C: Copy number gains on 22q13 in adenoid cystic carcinoma of the salivary gland revealed by comparative genomic hybridization and tissue microarray analysis. Cancer Genet Cytogenet; 2005 May;159(1):89-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Copy number gains on 22q13 in adenoid cystic carcinoma of the salivary gland revealed by comparative genomic hybridization and tissue microarray analysis.
  • Adenoid cystic carcinoma (ACC) of the salivary gland is a neoplasm characterized by slow but inevitable local progression and terminal hematogenous metastasis.
  • We therefore assume that copy number gain of 22q13 is a novel frequent finding in ACC that may be involved in the initial pathogenesis of this neoplasm by proto-oncogene activation.
  • [MeSH-major] Carcinoma, Adenoid Cystic / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 22 / genetics. Microarray Analysis. Nucleic Acid Hybridization. Salivary Gland Neoplasms / genetics

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860365.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


12. Zhang N, Zhang DS, Han JQ, Zhang SZ, Liu GJ, Wei FC, Zhang J, Mu WL: [Radiosensitization by double suicide gene system in ACC-2 cell]. Shanghai Kou Qiang Yi Xue; 2009 Apr;18(2):183-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To investigate the radiosensitization by prodrug and CD-TK double suicide gene therapy system in adenoid cystic carcinoma cells (ACC-2).
  • [MeSH-minor] Carcinoma, Adenoid Cystic. Cell Line, Tumor. Genetic Therapy. Humans. Plasmids. Transfection. X-Rays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417997.001).
  • [ISSN] 1006-7248
  • [Journal-full-title] Shanghai kou qiang yi xue = Shanghai journal of stomatology
  • [ISO-abbreviation] Shanghai Kou Qiang Yi Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.1.21 / Thymidine Kinase; EC 3.5.4.1 / Cytosine Deaminase
  •  go-up   go-down


13. Dequanter D, Andry G, Lothaire P, Larsimont D, Deraemaecker R: Wide localized excision and reconstruction for minor salivary gland tumours. B-ENT; 2005;1(4):187-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Four consecutive patients suffering from minor salivary gland tumours of the upper aerodigestive tract were treated: two had adenoid cystic carcinomas (one of the lateral oropharyngeal mucosa, one of the retromolar area); one had a polymorphous low-grade carcinoma (at the base of the tongue); and one had mucoepidermoid carcinoma (on the floor of the mouth).
  • Two patients, locally controlled, with adenoid cystic carcinomas died: one from brain metastases (four years post-surgery), the other with pulmonary metastases (eight-years post-surgery).
  • One patient is alive with a recurrent tumour of the pterygomaxillary fossa (without trismus) sixteen years after the original operation; another patient is free of recurrent disease at the base of the tongue but has recently undergone surgery, with success, for two pulmonary metastases sixty months after the initial surgery.
  • CONCLUSIONS: For minor salivary gland carcinoma of the head and neck, large resection with immediate reconstruction affords fast recovery and long-lasting locoregional control.
  • [MeSH-major] Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / surgery. Neck Dissection / methods. Reconstructive Surgical Procedures / methods. Salivary Gland Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16429751.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


14. Ayadi K, Ayadi L, Daoud E, Mnif Z, Ben Mahfoudh K, Boudawara T, Mnif J: Adenoid cystic carcinoma of the parotid with facial nerve invasion. Tunis Med; 2010 Jan;88(1):46-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the parotid with facial nerve invasion.
  • BACKGROUND: Adenoid cystic carcinoma comprises approximately 10% of all epithelial salivary neoplasms and most frequently involves the parotid.
  • AIM: The authors report a case of parotid adenoid cystic carcinoma with invasion and spread via the facial nerve with an emphasis on radiologic features.
  • OBSERVATION: We report a case of a 47-year-old man presenting with a right submandibular mass evolving for 4 years.
  • Pathologic examination of the resected specimen revealed histological features of adenoid cystic carcinoma with intra neural invasion of the mastoid segment of the facial nerve.
  • CONCLUSION: This study confirms that multiplanar approach of MRI allows rapid detection of adenoid cystic carcinoma.
  • [MeSH-major] Carcinoma, Adenoid Cystic / diagnosis. Facial Nerve / pathology. Parotid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20415214.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


15. Mataix J, Bañuls J, Botella R, Laredo C, Lucas A: [Brooke-Spiegler syndrome: an heterogeneous entity]. Actas Dermosifiliogr; 2006 Dec;97(10):669-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Síndrome de Brooke-Spiegler: una entidad heterogénea.
  • The Brooke-Spiegler syndrome is a rare, autosomally dominant disease with a predisposition to develop different adnexal tumors.
  • Clinically it is characterized by the presence of multiple cylindromas, trichoepitheliomas, and occasionally, spiradenomas.
  • In this article we present the case of a woman and her daughter, both affected by this rare genodermatosis.
  • [MeSH-major] Carcinoma, Adenoid Cystic / genetics. Neoplasms, Basal Cell / genetics. Neoplasms, Multiple Primary / genetics. Neoplastic Syndromes, Hereditary / genetics. Skin Neoplasms / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Child. Facial Neoplasms / diagnosis. Facial Neoplasms / genetics. Female. Genes, Dominant. Humans. Phenotype

  • Genetic Alliance. consumer health - Brooke-Spiegler syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17173833.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / Tumor Suppressor Proteins
  • [Number-of-references] 30
  •  go-up   go-down


16. Zeng Q, Tang PZ, Xu ZG, Qi YF, Wu XX, Liu WS: [Malignant minor salivary gland tumors of the larynx]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Jan;44(1):40-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten patients (66.7%) had adenoid cystic carcinoma and 2 (13.3%) had adenocarcinoma.
  • The other three patients had mucoepidermoid carcinomas, polymorphic adenocarcinoma and base cell carcinoma respectively.
  • Five patients were found to have recurrent disease, 4 of whom underwent salvage surgery, 1 of whom had palliation radiotherapy.
  • Five patients have no evidence of disease, 1 of whom had surgery alone, 4 of whom were treated with surgery plus radiotherapy.
  • Seven patients developed recurrent disease, 1 of whom had local recurrence alone, 1 had regional recurrence alone, 2 had distant metastases alone, and 3 had local and distant metastases.
  • CONCLUSIONS: Minor salivary gland carcinomas of the larynx are rare and they are prone to the local recurrence and the distant metastasis in advanced stage.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19484987.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Chang CH, Shu MT, Lee JC, Leu YS, Chen YC, Lee KS: Treatments and outcomes of malignant tumors of external auditory canal. Am J Otolaryngol; 2009 Jan-Feb;30(1):44-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Primary cancer of the external auditory canal (EAC) is a rare disease with poor prognosis.
  • METHODS: We retrospectively reviewed the patients treated for primary cancer of EAC between 1991 and 2002 at our hospital, which is a tertiary referral center.
  • RESULTS: Ten patients had squamous cell carcinoma and 2 had adenoid cystic carcinoma (ACC).
  • Five patients had stage I disease, 2 with stage II, 1 with stage III, and 4 with stage IV.
  • All patients (n = 7) with early stage (I or II) were disease-free, but only 1 of 5 patients with late stage (III or IV) was disease-free.
  • Only one patient with complete resection had recurrence and the histologic diagnosis of this particular patient was ACC.
  • CONCLUSIONS: Patients with early-stage cancer can benefit from less aggressive surgical interventions without significant morbidity or mortality.
  • No recurrence occurred in patients with complete resection except the one with ACC.
  • The result of our institute was comparable or superior to those of other studies in early-stage disease.
  • However, patients with advanced cancer had high recurrence rate despite of adjuvant radiotherapy, suggesting more aggressive surgical approach for complete resection was necessary.
  • [MeSH-minor] Adult. Aged. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Otologic Surgical Procedures / methods. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Taiwan

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19027512.001).
  • [ISSN] 1532-818X
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Musani MA, Sohail Z, Zafar S, Malik S: Morphological pattern of parotid gland tumours. J Coll Physicians Surg Pak; 2008 May;18(5):274-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic adenoma was most common benign tumor (83.5%), followed by Warthins tumour.
  • The most common malignant tumour was mucoepidermoid carcinoma (60%), followed by adenoid cystic carcinoma.
  • Parotid swelling for years was main feature of benign tumours, whereas malignant tumours presented with pain, fixation to skin or underlying structure, cervical lymphadenopathy and facial palsy.
  • CONCLUSION: Pleomorphic adenoma was the most common benign tumour and mucoepidermoid carcinoma was most common malignant tumour.
  • [MeSH-major] Parotid Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Fine-Needle. Child. Diagnosis, Differential. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Morbidity / trends. Neoplasm Staging / methods. Pakistan / epidemiology. Retrospective Studies. Severity of Illness Index. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541080.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Pakistan
  •  go-up   go-down


19. Trepp R, Padberg BC, Varga Z, Cathomas R, Inauen R, Reinhart WH: Extensive extranodal metastases of basal-like breast cancer with predominant myoepithelial spindle cell differentiation. Pathol Res Pract; 2010 May 15;206(5):334-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive extranodal metastases of basal-like breast cancer with predominant myoepithelial spindle cell differentiation.
  • These include multifocal myoepitheliomatosis, the rare mixed tumor or pleomorphic adenoma, adenoid cystic carcinoma, adenomyoepithelioma and myoepithelial carcinoma (malignant myoepithelioma).
  • Myoepithelial carcinoma is the only lesion purely composed of myoepithelial cells.
  • In contrast to the statement of the current World Health Organization (WHO), recent studies have reported that regional and distant metastases may occur in about 50% of pure myoepithelial carcinomas.
  • The presented case of a breast carcinoma with dominant myoepithelial/spindle cell differentiation in a 58-year-old woman is an excellent example to document the highly aggressive biological behavior of this tumor phenotype.
  • Despite an extensive chemotherapy and radiotherapy, the tumor was rapidly progressive, forming a finally exulcerating local tumor relapse and widespread metastases to the myocardium, lungs, liver, kidneys and skin.
  • Similarities in morphology and biological behavior compared to patients with "triple-negative" (hormone receptor and Her2) monophasic sarcomatoid carcinomas and pure spindle cell sarcomas are discussed.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / secondary. Kidney Neoplasms / secondary. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Skin Neoplasms / secondary


20. Lacrimal Gland Tumor Study Group: An epidemiological survey of lacrimal fossa lesions in Japan: number of patients and their sex ratio by pathological diagnosis. Jpn J Ophthalmol; 2005 Sep-Oct;49(5):343-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An epidemiological survey of lacrimal fossa lesions in Japan: number of patients and their sex ratio by pathological diagnosis.
  • PURPOSE: To report the results of a survey conducted on lacrimal fossa lesions in Japan.
  • We sent survey questionnaires to 1201 hospitals with training facilities accredited by the Japanese Ophthalmological Society and determined the number of patients and their sex ratio by pathological diagnosis.
  • RESULTS: Among tumors with high frequency, there were 86 cases of pleomorphic adenoma and 19 cases of adenoid cystic carcinoma in the category of epithelial tumor; 55 cases of malignant lymphoma and 32 cases of reactive lymphoid hyperplasia in the category of nonepithelial tumor; and 50 cases of inflammation and 22 cases of cystic lesion in the category of nonneoplastic lesion.
  • CONCLUSIONS: The sex ratio by pathological diagnosis revealed that women had a higher rate than men of pleomorphic adenoma, whereas men had a higher rate than women of malignant epithelial tumor.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chin Med J (Engl). 1992 Jun;105(6):481-5 [1333391.001]
  • [Cites] Am J Ophthalmol. 1956 Jan;41(1):3-11 [13275539.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):113-21 [6263450.001]
  • [Cites] Cancer. 1977 Feb;39(2):388-96 [189890.001]
  • [Cites] Br J Ophthalmol. 1992 Jul;76(7):401-7 [1320924.001]
  • [Cites] Ophthalmology. 1989 Apr;96(4):431-5 [2726173.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] Arch Otolaryngol. 1984 Mar;110(3):172-6 [6322732.001]
  • (PMID = 16187032.001).
  • [ISSN] 0021-5155
  • [Journal-full-title] Japanese journal of ophthalmology
  • [ISO-abbreviation] Jpn. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


21. Lupinetti AD, Roberts DB, Williams MD, Kupferman ME, Rosenthal DI, Demonte F, El-Naggar A, Weber RS, Hanna EY: Sinonasal adenoid cystic carcinoma: the M. D. Anderson Cancer Center experience. Cancer; 2007 Dec 15;110(12):2726-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal adenoid cystic carcinoma: the M. D. Anderson Cancer Center experience.
  • BACKGROUND: Adenoid cystic carcinoma of the sinonasal tract is a rare cancer that accounts for 10% of all malignancies at this site.
  • The objective of the current study was to evaluate prognostic factors, treatment outcomes, recurrence patterns, and survival rates for sinonasal adenoid cystic carcinoma.
  • Between 1990 and 2004, 105 patients were evaluated for adenoid cystic carcinoma of the sinonasal tract at a single institution.
  • RESULTS: One hundred five patients with adenoid cystic carcinoma were evaluated, including 58 women and 47 men.
  • The majority of patients presented with T3/T4 (76.7%), N0 (98%), M0 (97%) disease.
  • Eighty-four percent of patients underwent surgery and received postoperative radiation as treatment for their primary disease.
  • The 5-year overall survival and disease specific survival rates were 62.9% and 70.9%, respectively.
  • CONCLUSIONS: Adenoid cystic carcinoma of the paranasal sinuses is a rare disease, and the ideal treatment paradigm has yet to be defined.
  • Although local recurrences develop in a significant percentage of patients, survival from this disease exceeds that of other sinonasal malignancies.
  • [MeSH-major] Carcinoma, Adenoid Cystic / therapy. Paranasal Sinus Neoplasms / therapy

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 American Cancer Society
  • (PMID = 17960615.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Yasuda M, Hanagiri T, Ichiki Y, Uramoto H, Takenoyama M, Yasumoto K: Surgical treatment of patients with stenosis of the central airway due to tracheal tumours. Asian J Surg; 2010 Oct;33(4):212-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common histological finding was thyroid carcinoma (n = 3), followed by adenoid cystic carcinoma (n = 2), a metastatic thyroid tumour (n = 1), and a benign granular cell tumour (n = 1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Asian Surgical Association. Published by Elsevier B.V. All rights reserved.
  • (PMID = 21377110.001).
  • [ISSN] 0219-3108
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Kato N, Takeda J, Fukase M, Motoyama T: Alternate mucoid and hyalinized stroma in clear cell carcinoma of the ovary: manifestation of serial stromal remodeling. Mod Pathol; 2010 Jun;23(6):881-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternate mucoid and hyalinized stroma in clear cell carcinoma of the ovary: manifestation of serial stromal remodeling.
  • The stroma in ovarian clear cell carcinoma often shows alternate mucoid and hyalinized change.
  • We examined 60 ovarian clear cell carcinomas for the distribution and nature of the mucoid stroma.
  • Twenty-nine of 60 (48%) clear cell carcinomas showed a mucoid stroma, either focally (21 cases) or diffusely (8 cases).
  • The mucoid stroma in clear cell carcinomas was distinct from that in other surface epithelial tumors as follows: it showed a compact spherule-like appearance, commonly occupying the cores of small papillae.
  • It also exhibited a cribriform pattern, resembling that of adenoid cystic carcinoma.
  • Among 40 clear cell carcinomas that had at least one type of stroma, 26 (65%) had both, either concomitantly or separately.
  • In vitro, a clear cell carcinoma cell line, HAC-2, formed a spherule-like structure containing hyaluronan in the center, and a significant amount of hyaluronan was detected by latex agglutination immunoturbidimetry, indicating that HAC-2 itself has the potential to produce hyaluronan.
  • All of these facts indicate that the spherule-like mucoid stroma and hyalinized stroma represent different phases of the stromal remodeling process, which is promoted by the deposition of different extracellular matrices produced by clear cell carcinoma cells.
  • The spherule-like mucoid stroma and hyalinized stroma are considered complementary diagnostic signatures of ovarian clear cell carcinoma.
  • [MeSH-major] Carcinoma / metabolism. Extracellular Matrix / metabolism. Hyaluronic Acid / metabolism. Mucins / metabolism. Ovarian Neoplasms / metabolism. Stromal Cells / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Animals. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305617.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


24. Thorup C, Sebbesen L, Danø H, Leetmaa M, Andersen M, Buchwald C, Kristensen CA, Bentzen J, Godballe C, Johansen J, Grau C: Carcinoma of the nasal cavity and paranasal sinuses in Denmark 1995-2004. Acta Oncol; 2010 Apr;49(3):389-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the nasal cavity and paranasal sinuses in Denmark 1995-2004.
  • OBJECTIVE: To evaluate the treatment outcome for sino-nasal carcinomas in Denmark from 1995-2004 and compare the results to the previous Danish survey covering 1982-1991.
  • MATERIALS AND METHODS: In the five Danish head and neck oncology centres, charts of all consecutive patients with sino-nasal carcinomas were reviewed and data extracted to a common database.
  • Histologies included squamous cell carcinoma (55%), adenocarcinoma (28.5%), adenoid-cystic carcinoma (5.0%), undifferentiated carcinoma (4.5%), transitiocellular carcinoma (1.7%), mucoepidermoid carcinoma (0.8%), neuroendocrine carcinoma (2.5%), small cell carcinomas (1.2%) and carcinomas not otherwise specified (0.8%).
  • The overall 5-year actuarial survival rate for the entire cohort was 47 + or - 3%, and the corresponding cancer-specific 5-year actuarial survival rate was 57 + or - 3%.
  • Female gender, nasal cavity tumour, adenocarcinoma and low clinical stage were significant positive prognostic factors in univariate analysis.
  • Compared to the previous Danish survey covering the period 1982-1991, the overall survival and cancer-specific survival rates have improved significantly.
  • [MeSH-major] Carcinoma / epidemiology. Nose Neoplasms / epidemiology. Paranasal Sinus Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adult. Aged. Aged, 80 and over. Carcinoma, Mucoepidermoid / epidemiology. Carcinoma, Neuroendocrine / epidemiology. Carcinoma, Small Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Transitional Cell / epidemiology. Cystadenocarcinoma / epidemiology. Denmark / epidemiology. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Proportional Hazards Models

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20001493.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


25. Miettinen M, Lasota J: KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol; 2005 Sep;13(3):205-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD117 (KIT) is a type III receptor tyrosine kinase operating in cell signal transduction in several cell types.
  • Other KIT-positive normal cells include epithelial cells in skin adnexa, breast, and subsets of cerebellar neurons.
  • Also, KIT is expressed in pulmonary and other small cell carcinomas, adenoid cystic carcinoma, renal chromophobe carcinoma, thymic, and some ovarian and few breast carcinomas.
  • KIT deficiency due to hereditary nonsense/missense mutations leads to disruption of KIT-dependent functions such as erythropoiesis, skin pigmentation, fertility, and gastrointestinal motility.
  • KIT tyrosine kinase inhibitors such as imatinib mesylate are the generally accepted treatment of metastatic GISTs, and their availability has prompted an active search for other treatment targets among KIT-positive tumors such as myeloid leukemias and small cell carcinoma of the lung, with variable and often nonconvincing results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16082245.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 239
  •  go-up   go-down


26. Le Tourneau C: [Molecularly targeted therapy in head and neck cancer]. Bull Cancer; 2010 Dec;97(12):1453-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecularly targeted therapy in head and neck cancer].
  • Head and neck squamous cell carcinomas (HNSCC) were indeed one of the first tumor types to get a molecularly targeted agent approved (cetuximab, a monoclonal antibody targeting EGFR), not only in the recurrent or metastatic setting but also in the locally advanced setting.
  • This article summarizes recent data on molecularly targeted agents in most frequent head and neck cancers including HNSCC, nasopharyngeal carcinoma and adenoid cystic carcinoma of salivary glands.
  • [MeSH-minor] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal, Humanized. Carcinoma, Adenoid Cystic / drug therapy. Cetuximab. Cisplatin / therapeutic use. Combined Modality Therapy / methods. Humans. Nasopharyngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Protein Kinase Inhibitors / therapeutic use. Randomized Controlled Trials as Topic. Salivary Gland Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21134823.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin; Nasopharyngeal carcinoma
  •  go-up   go-down


27. Bittner N, Koh WJ, Laramore GE, Patel S, Mulligan MS, Douglas JG: Treatment of locally advanced adenoid cystic carcinoma of the trachea with neutron radiotherapy. Int J Radiat Oncol Biol Phys; 2008 Oct 1;72(2):410-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of locally advanced adenoid cystic carcinoma of the trachea with neutron radiotherapy.
  • PURPOSE: To examine the efficacy of fast neutron radiotherapy in the treatment of locally advanced adenoid cystic carcinoma (ACC) of the trachea and to compare outcomes with and without high-dose-rate (HDR) endobronchial brachytherapy boost.
  • CONCLUSIONS: Fast neutron radiotherapy is an effective treatment for locally advanced adenoid cystic carcinoma of the trachea, with acceptable treatment-related toxicity.
  • [MeSH-major] Carcinoma, Adenoid Cystic / radiotherapy. Neutrons / therapeutic use. Tracheal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18374509.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iridium Radioisotopes
  •  go-up   go-down


28. Li Y, Zhang TM, An YZ, Shi JT, Fu JD, Qiu E: [Clinical study of lacrimal gland tumor involving anterior and middle cranial fossae]. Zhonghua Yi Xue Za Zhi; 2006 Jun 20;86(23):1597-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A retrospective study was conducted on the clinical data of 23 cases lacrimal gland tumor involving the anterior and middle cranial fossae confirmed by radiological examination, including 11 cases of adenoid cystic carcinoma, 6 cases of pleomorphic adenocarcinoma (malignant mixed tumor), 2 cases of adenocarcinoma, 1 case of squamous cell carcinoma, 1 case of ductal carcinoma, 1 case of mucoepidermoid carcinoma, and 1 case of benign mixed tumor, 15 males and 8 females, aged 42.5 (2 - 76), with a case history of 43 months (2 months to 27 years), with the chief complaints of progressive proptosis, disgenesia of the eye ball, and orbit pain, all undergoing transcranial-orbital operation from August 1998 to February. 2006.
  • Recurrence of tumor occurred in 4 cases, and 1 case died from distant metastasis of adenocarcinoma.
  • CONCLUSIONS: Malignant lacrimal gland tumors, mainly adenoid cystic carcinomas, incline to involve the anterior and middle cranial fossae.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16854296.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


29. Subhashraj K, Orafi M, Nair KV, El-Gehani R, Elarbi M: Primary malignant tumors of orofacial region at Benghazi, Libya: a 17 years review. Cancer Epidemiol; 2009 Nov;33(5):332-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the epithelial tumors, squamous cell carcinoma (50.6%) was the most common neoplasm, followed by mucoepidermoid carcinoma (15%) and adenoid cystic carcinoma (8.7%).

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19932650.001).
  • [ISSN] 1877-783X
  • [Journal-full-title] Cancer epidemiology
  • [ISO-abbreviation] Cancer Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 35
  •  go-up   go-down


30. Moore MG, Deschler DG, McKenna MJ, Varvares MA, Lin DT: Management outcomes following lateral temporal bone resection for ear and temporal bone malignancies. Otolaryngol Head Neck Surg; 2007 Dec;137(6):893-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In this group of 35 patients, the mean age was 62.7 years, with tumor histopathologies including squamous cell carcinoma (SCC, 20), basal cell carcinoma (BCC, 7), adenoid cystic carcinoma (ACC, 7), and adenocarcinoma (1).
  • The 5-year overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) were 77%, 79%, and 52%, respectively.
  • CONCLUSIONS: In patients with carcinomas of the ear and temporal bone, upfront excision including LTBR is an effective management when combined with postoperative radiation therapy.
  • Complete removal of all disease may improve survival and decrease recurrence.
  • [MeSH-minor] Adenocarcinoma / surgery. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Ear Canal / surgery. Ear, External / surgery. Ear, Middle / surgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Parotid Gland / surgery. Retrospective Studies. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18036417.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Lima RA, Tavares MR, Dias FL, Kligerman J, Nascimento MF, Barbosa MM, Cernea CR, Soares JR, Santos IC, Salviano S: Clinical prognostic factors in malignant parotid gland tumors. Otolaryngol Head Neck Surg; 2005 Nov;133(5):702-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To analyze the factors in parotid malignant epithelial tumors influencing recurrences and disease-specific survival.
  • The influence of selected factors on the 10 year disease-specific survival was analyzed using the Kaplan-Meier actuarial method and the log-rank test.
  • RESULTS: Forty patients had mucoepidermoid carcinoma, 18 patients adenocarcinoma NOS, 18 patients acinic cell carcinoma, 15 patients adenoid cystic carcinoma, 11 patients malignant mixed tumor, 11 patients salivary duct carcinoma, and 13 patients other pathology.
  • The 10-year disease-specific survival was 97% for stage I, 81% for stage II, 56% for stage III, and 20% for stage IV.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / therapy. Neoplasm Invasiveness / pathology. Parotid Neoplasms / mortality. Parotid Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16274796.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Schwentner I, Obrist P, Thumfart W, Sprinzl G: Distant metastasis of parotid gland tumors. Acta Otolaryngol; 2006 Apr;126(4):340-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of distant metastasis in head and neck cancer and especially in salivary gland cancer is relatively low in comparison to other malignancies.
  • However, the presence of distant metastasis heralds a poor prognosis in head and neck cancer, with a median survival of 4.3-7.3 months.
  • The likelihood of developing distant metastasis is associated with high-grade tumors, such as adenoid cystic carcinoma, salivary duct carcinoma, high-grade mucoepidermoid carcinoma and tumors located in the submandibular gland, posterior tongue and pharyngeal tumors.
  • On the basis of a clinical case regarding a patient with metastatic parotid gland cancer we present a review of the literature.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Ileal Neoplasms / secondary. Parotid Neoplasms / pathology
  • [MeSH-minor] Aged. Bone Neoplasms / secondary. Brain Neoplasms / secondary. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / secondary. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / secondary. Carcinoma, Mucoepidermoid / pathology. Carcinoma, Mucoepidermoid / secondary. Fatal Outcome. Humans. Immunohistochemistry. Incidence. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Parotid Gland / pathology. Parotid Gland / surgery. Salivary Ducts / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608783.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 32
  •  go-up   go-down


33. Handra-Luca A, Planchard D, Fouret P: Docetaxel-cisplatin-radiotherapy in adenoid cystic carcinoma with high-grade transformation. Oral Oncol; 2009 Nov;45(11):e208-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel-cisplatin-radiotherapy in adenoid cystic carcinoma with high-grade transformation.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Adenoid Cystic / therapy. Maxillary Sinus Neoplasms / therapy. Mouth Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy / methods. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy. Radiotherapy, Conformal. Taxoids / administration & dosage. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502105.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


34. Macarenco RS, Uphoff TS, Gilmer HF, Jenkins RB, Thibodeau SN, Lewis JE, Molina JR, Yang P, Aubry MC: Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. Mod Pathol; 2008 Sep;21(9):1168-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study.
  • Salivary gland-type lung carcinomas are uncommon neoplasms of the lung, the two most common being adenoid cystic carcinoma and mucoepidermoid carcinoma.
  • Although they usually have an indolent behavior, adenoid cystic carcinomas can be more aggressive, with 5-year survival as low as 55%.
  • In contrast to the most common subtypes of lung carcinomas, epidermal growth factor receptor studies have not been carried out in this group of tumors.
  • Herein we report a series of 24 cases (12 adenoid cystic and 12 mucoepidermoid carcinomas) tested for epidermal growth factor receptor protein expression, epidermal growth factor receptor gene copy gains, and epidermal growth factor receptor gene mutational status, through immunohistochemistry, fluorescence in situ hybridization, and sequencing of the exons 18-21, respectively.
  • Overall, 91 and 92% of the adenoid cystic carcinomas and mucoepidermoid carcinomas expressed epidermal growth factor receptor protein.
  • Chromosome 7 polysomy occurred in 25% of the cases (four adenoid cystic carcinomas and two mucoepidermoid carcinomas).
  • Immunoexpression of epidermal growth factor receptor in salivary gland-type lung carcinomas is not related to epidermal growth factor receptor gene copy number or mutational status.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 1999 Feb;109(1):66-9 [9973962.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Cancer. 2005 Feb 1;103(3):630-6 [15630697.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):133-44 [16014883.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6838-45 [15998906.001]
  • [Cites] Hum Pathol. 2005 Oct;36(10):1127-34 [16226114.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jul 1;152(1):15-22 [15193437.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):895-904 [15143334.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1987;411(6):499-507 [2823456.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1989;415(6):523-31 [2508310.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):400-4 [1670993.001]
  • [Cites] Genes Chromosomes Cancer. 1991 Jan;3(1):21-3 [1648955.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jun;74(2):77-83 [8019965.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jul 15;75(2):133-8 [8055477.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jul 15;75(2):150-2 [8055481.001]
  • [Cites] Clin Neuropathol. 1995 May-Jun;14(3):169-74 [7671460.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Aug;82(2):187-92 [8863309.001]
  • [Cites] Virchows Arch. 1997 Apr;430(4):339-42 [9134046.001]
  • [Cites] Virchows Arch. 2005 Dec;447(6):969-77 [16158183.001]
  • [Cites] Int J Cancer. 2006 Mar 1;118(5):1173-80 [16161046.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2498-504 [16353158.001]
  • [Cites] Jpn J Clin Oncol. 2006 Feb;36(2):69-75 [16449241.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Apr;3(4):170-1 [16596125.001]
  • [Cites] Am J Clin Pathol. 2006 Jun;125(6):860-5 [16690485.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2696-705 [17121916.001]
  • [Cites] J Thorac Oncol. 2007 May;2(5):414-22 [17473657.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3978-84 [17761983.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2253-9 [17918258.001]
  • [Cites] Lab Invest. 2008 May;88(5):464-73 [18332873.001]
  • [Cites] Cell. 2000 Oct 13;103(2):211-25 [11057895.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Proc Natl Sci Counc Repub China B. 2001 Apr;25(2):90-6 [11370765.001]
  • [Cites] Laryngoscope. 2001 Aug;111(8):1373-8 [11568571.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 5;94(11):855-7 [12048274.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):857-65 [15681531.001]
  • (PMID = 18587327.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090628-08; United States / NCI NIH HHS / CA / K12 CA090628; United States / NCI NIH HHS / CA / K12 CA090628-08
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ NIHMS121772; NLM/ PMC2752817
  •  go-up   go-down


35. Blake PW, Toro JR: Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling. Hum Mutat; 2009 Jul;30(7):1025-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Germline mutations in the cylindromatosis (CYLD) gene have been described in families with cylindromas, trichoepitheliomas, and/or spiradenomas.
  • Brooke-Spiegler syndrome (BSS) is the autosomal dominant predisposition to skin appendageal neoplasms including cylindromas, trichoepitheliomas, and/or spiradenomas.


36. Otsuka H, Graham MM, Kogame M, Nishitani H: The impact of FDG-PET in the management of patients with salivary gland malignancy. Ann Nucl Med; 2005 Dec;19(8):691-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology consisted of 8 adenocarcinomas, 8 squamous cell carcinomas, 4 adenoid cystic carcinomas, 4 carcinoma ex pleomorphic adenomas, 2 mucoepidermoid carcinomas, 2 poorly differentiated carcinomas, 1 salivary duct carcinoma, 1 lymphoepithelial carcinoma and 1 melanoma.
  • RESULTS: In the initial staging group, all 12 primary lesions (100%) showed positive FDG uptake (5 squamous cell carcinomas, 2 adenocarcinomas, 2 poorly differentiated carcinomas, 1 carcinoma ex pleomorphic adenoma, 1 salivary duct carcinoma, 1 lymphoepithelial carcinoma).
  • Three patients (25%) had FDG positive distant disease (liver, bone, lymph nodes); surgery was canceled and therapy changed to chemoradiation.
  • In the restaging group (33 studies in 23 patients), 5 patients (22%) had FDG positive distant disease, which changed the treatment from surgery to chemoradiation or other.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444995.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


37. Kassam AB, Prevedello DM, Carrau RL, Snyderman CH, Gardner P, Osawa S, Seker A, Rhoton AL Jr: The front door to meckel's cave: an anteromedial corridor via expanded endoscopic endonasal approach- technical considerations and clinical series. Neurosurgery; 2009 Mar;64(3 Suppl):ons71-82; discussion ons82-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most frequent abnormalities encountered were adenoid cystic carcinoma, meningioma, and schwannomas.
  • [MeSH-major] Carcinoma, Adenoid Cystic / surgery. Cranial Fossa, Middle / surgery. Endoscopy / methods. Meningioma / surgery. Nasal Cavity / surgery. Neurilemmoma / surgery. Neurosurgical Procedures / methods. Skull Base Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19240575.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Bilsky MH, Bentz B, Vitaz T, Shah J, Kraus D: Craniofacial resection for cranial base malignancies involving the infratemporal fossa. Neurosurgery; 2005 Oct;57(4 Suppl):339-47; discussion 339-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: At Memorial Sloan-Kettering Cancer Center, 25 patients underwent anterolateral cranial base resections for tumors that involved the infratemporal fossa during a 7-year period.
  • The most common tumors were sarcoma (n = 9), squamous cell carcinoma (n = 6), and adenoid cystic carcinoma (n = 3).
  • Twelve patients underwent Type 1 dissection for tumors involving only the infratemporal fossa and maxillary sinus; 2 patients underwent Type 2 dissections involving the infratemporal fossa and anterior cranial base; and 11 patients underwent Type 3 dissection, which included the infratemporal fossa, anterior cranial base, and orbit.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1988 May;68(5):678-83 [2833586.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 Sep;118(9):913-7 [1503715.001]
  • [Cites] Head Neck. 1994 Jul-Aug;16(4):307-12 [8056574.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):481-4 [7977980.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Jul;123(7):738-42 [9236594.001]
  • [Cites] Am J Surg. 1997 Nov;174(5):565-8 [9374239.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 Jan;120(1):17-24 [9914544.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Nov;125(11):1252-7 [10555698.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1385-98 [10598707.001]
  • [Cites] Head Neck. 2000 Dec;22(8):772-80 [11084637.001]
  • [Cites] Head Neck. 2003 Jul;25(7):515-20 [12808653.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1179-87 [12973841.001]
  • [Cites] Laryngoscope. 1983 Jan;93(1):36-44 [6185810.001]
  • [Cites] Radiology. 1984 Oct;153(1):149-56 [6089262.001]
  • [Cites] J Neurosurg. 1987 Oct;67(4):488-99 [3655886.001]
  • (PMID = 16234683.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009685
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS15707; NLM/ PMC1858642
  •  go-up   go-down


39. Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL: Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol; 2005 Jan 20;23(3):585-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
  • PURPOSE: This study aimed to assess the antitumor activity of imatinib in adenoid cystic carcinoma (ACC) of the salivary gland expressing c-kit.
  • A high level of c-kit expression has been identified in more than 90% of ACCs.
  • Nine patients had stable disease as best response.
  • Six patients had progressive disease after two cycles.
  • Overexpression of wild-type c-kit was not sufficient for clinical benefit from imatinib in ACC.
  • Accrual to this study was rapid for a relatively rare cancer, encouraging additional efforts to identify more effective systemic therapy for these patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / drug therapy. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / biosynthesis. Pyrimidines / therapeutic use. Salivary Gland Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Sep 1;23(25):6271-3; author reply 6273-4 [16135502.001]
  • (PMID = 15659505.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01 CM 17102-01; United States / NCI NIH HHS / CM / N01 CM 17107-01
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


40. Retamar RA, Stengel F, Saadi ME, Kien MC, Della Giovana P, Cabrera H, Chouela EN: Brooke-Spiegler syndrome - report of four families: treatment with CO2 laser. Int J Dermatol; 2007 Jun;46(6):583-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Brooke-Spiegler syndrome is a well known but rare cutaneous disorder characterized by the presence of multiple trichoepitheliomas and cylindromas.
  • [MeSH-major] Adenoma, Sweat Gland / surgery. Carcinoma, Adenoid Cystic / surgery. Laser Therapy. Neoplasms, Adnexal and Skin Appendage / surgery. Neoplasms, Multiple Primary / surgery. Neoplastic Syndromes, Hereditary / surgery. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Brooke-Spiegler syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550556.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Pommier P, Liebsch NJ, Deschler DG, Lin DT, McIntyre JF, Barker FG 2nd, Adams JA, Lopes VV, Varvares M, Loeffler JS, Chan AW: Proton beam radiation therapy for skull base adenoid cystic carcinoma. Arch Otolaryngol Head Neck Surg; 2006 Nov;132(11):1242-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton beam radiation therapy for skull base adenoid cystic carcinoma.
  • OBJECTIVE: To determine the treatment outcome and prognostic factors in patients with adenoid cystic carcinoma of the skull base treated with proton beam radiation therapy.
  • PATIENTS: From 1991 to 2002, 23 patients with newly diagnosed adenoid cystic carcinoma with skull base extension were treated with combined proton and photon radiotherapy.
  • MAIN OUTCOME MEASURES: Locoregional control and disease-free survival and overall survival rates.
  • The disease-free and overall survival rates at 5 years were 56% and 77%, respectively.
  • CONCLUSIONS: High-dose conformal proton beam radiation therapy results in a very encouraging local control rate in patients with adenoid cystic carcinoma of the skull base.
  • [MeSH-major] Carcinoma, Adenoid Cystic / radiotherapy. Skull Base Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Carbon. Cavernous Sinus. Cranial Fossa, Posterior. Disease-Free Survival. Female. Humans. Male. Middle Aged. Nasopharyngeal Neoplasms / pathology. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neutrons. Paranasal Sinus Neoplasms / pathology. Prognosis. Protons. Radiotherapy / adverse effects. Radiotherapy Dosage. Retrospective Studies. Salvage Therapy. Sphenoid Sinus. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17116822.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons; 7440-44-0 / Carbon
  •  go-up   go-down


42. Gomez DR, Hoppe BS, Wolden SL, Zhung JE, Patel SG, Kraus DH, Shah JP, Ghossein RA, Lee NY: Outcomes and prognostic variables in adenoid cystic carcinoma of the head and neck: a recent experience. Int J Radiat Oncol Biol Phys; 2008 Apr 1;70(5):1365-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes and prognostic variables in adenoid cystic carcinoma of the head and neck: a recent experience.
  • PURPOSE: To analyze the recent experience of patients with adenoid cystic carcinoma treated with radiation therapy at Memorial Sloan-Kettering Cancer Center.
  • METHODS AND MATERIALS: From 1990 to 2004, a total of 59 patients with a diagnosis of primary adenoid cystic carcinoma of the head and neck received radiation therapy at our institution.
  • Five-year and 10-year rates of disease-free and overall survival were 76%/40% and 87%/65%, respectively.
  • [MeSH-major] Carcinoma, Adenoid Cystic / radiotherapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiation Injuries / complications. Radiotherapy, Conformal / methods. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18029108.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Sbitti Y, Kadiri H, Fetohi M, Elghissassi I, M'rabti H, Boutayeb S, Ichou M, Boussen H, Errihani H: [Primary adenoid cystic carcinoma in breast]. Cancer Radiother; 2009 Jan;13(1):65-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenoid cystic carcinoma in breast].
  • [Transliterated title] Carcinome adénoïde kystique primitif du sein.
  • Adenoid cystic carcinoma (ACC) of the breast is a rare neoplasm.
  • Diagnosis was based on final histopathological exam completed by immunohistochemistry or after slides review.
  • [MeSH-major] Breast Neoplasms. Carcinoma, Adenoid Cystic

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097926.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 18
  •  go-up   go-down


44. Sun ZJ, Chen G, Hu X, Zhang W, Liu Y, Zhu LX, Zhou Q, Zhao YF: Activation of PI3K/Akt/IKK-alpha/NF-kappaB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: its inhibition by quercetin. Apoptosis; 2010 Jul;15(7):850-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of PI3K/Akt/IKK-alpha/NF-kappaB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: its inhibition by quercetin.
  • The present study was to investigate the effects of quercetin on growth and apoptosis in human salivary adenoid cystic carcinoma (ACC).
  • [MeSH-major] Antineoplastic Agents / toxicity. Apoptosis. Carcinoma, Adenoid Cystic / metabolism. Quercetin / toxicity. Salivary Gland Neoplasms / metabolism. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. QUERCETIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20386985.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-bcl-2; 9007-43-6 / Cytochromes c; 9IKM0I5T1E / Quercetin; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.10 / I-kappa B Kinase; EC 3.4.22.- / Caspases
  •  go-up   go-down


45. Carlinfante G, Lazzaretti M, Ferrari S, Bianchi B, Crafa P: P53, bcl-2 and Ki-67 expression in adenoid cystic carcinoma of the palate. A clinico-pathologic study of 21 cases with long-term follow-up. Pathol Res Pract; 2005;200(11-12):791-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P53, bcl-2 and Ki-67 expression in adenoid cystic carcinoma of the palate. A clinico-pathologic study of 21 cases with long-term follow-up.
  • Adenoid cystic carcinoma (ACC) is an indolent tumor that pursues a protracted clinical course with recurrences and late metastases.
  • [MeSH-major] Carcinoma, Adenoid Cystic / secondary. Ki-67 Antigen / metabolism. Palatal Neoplasms / pathology. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792122.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


46. Ito FA, Ito K, Coletta RD, Graner E, de Almeida OP, Lopes MA: Salivary gland tumors: immunohistochemical study of EGF, EGFR, ErbB-2, FAS and Ki-67. Anal Quant Cytol Histol; 2009 Oct;31(5):280-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Immunohistochemical expression of epidermal growth factor (EGF), EGFR, ErbB-2, fatty acid synthase (FAS) and Ki-67 were analyzed in 41 pleomorphic adenoma (PA), in 30 mucoepidermoid carcinoma (MEC) and in 30 adenoid cystic carcinoma (ACC) and correlated with their histologic patterns.


47. Faivre S, Raymond E, Casiraghi O, Temam S, Berthaud P: Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol; 2005 Sep 1;23(25):6271-3; author reply 6273-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Adenoid Cystic / drug therapy. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / biosynthesis. Pyrimidines / therapeutic use. Salivary Gland Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2005 Jan 20;23(3):585-90 [15659505.001]
  • (PMID = 16135502.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


48. González-García R, Nam-Cha SH, Muñoz-Guerra MF, Gamallo-Amat C: Basal cell adenoma of the parotid gland. Case report and review of the literature. Med Oral Patol Oral Cir Bucal; 2006 Mar;11(2):E206-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the parotid gland. Case report and review of the literature.
  • Basal cell adenoma of the salivary glands is an uncommon type of monomorphous adenoma.
  • It is also characterized by the presence of a slack and hyaline stroma and the absence of myxoid or condroid stroma.
  • In contrast to pleomorphic adenoma, it tends to be multiple and its recurrence rate after surgical excision is high.
  • Due to prognostic implications, differential diagnosis with basal cell adenocarcinoma, adenoid cystic carcinoma and basaloid squamous cell carcinoma is mandatory.
  • We describe a case of basal cell adenoma of the parotid gland.
  • We also review the literature and discuss the diagnosis and management of this rare entity.
  • [MeSH-major] Adenoma / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16505803.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 21
  •  go-up   go-down


49. Kazakov DV, Soukup R, Mukensnabl P, Boudova L, Michal M: Brooke-Spiegler syndrome: report of a case with combined lesions containing cylindromatous, spiradenomatous, trichoblastomatous, and sebaceous differentiation. Am J Dermatopathol; 2005 Feb;27(1):27-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brooke-Spiegler syndrome: report of a case with combined lesions containing cylindromatous, spiradenomatous, trichoblastomatous, and sebaceous differentiation.
  • Brooke-Spiegler syndrome is an autosomal dominantly inherited disease with predisposition to cutaneous adnexal neoplasms, most commonly cylindromas and trichoepitheliomas.
  • The histopathological spectrum in our patient included cylindromas, spiradenomas, trichoepitheliomas, small nodular trichoblastomas, and lymphadenomas.
  • The occurrence of sebaceous and trichoblastic differentiation in spiradenocylindromas is a further proof that spiradenoma and cylindroma are not eccrine tumors but neoplasms of the folliculosebaceousapocrine unit.
  • [MeSH-major] Carcinoma, Skin Appendage / pathology. Neoplasms, Multiple Primary / pathology. Neoplastic Syndromes, Hereditary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adenoma, Sweat Gland / metabolism. Adenoma, Sweat Gland / pathology. Adenoma, Sweat Gland / surgery. Aged. Biomarkers, Tumor / metabolism. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / surgery. Hair Diseases / metabolism. Hair Diseases / pathology. Hair Diseases / surgery. Hair Follicle / metabolism. Hair Follicle / pathology. Humans. Immunoenzyme Techniques. Male. Sebaceous Glands / metabolism. Sebaceous Glands / pathology. Syndrome

  • Genetic Alliance. consumer health - Brooke-Spiegler syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15677973.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


50. Barrera JE, Shroyer KR, Said S, Hoernig G, Melrose R, Freedman PD, Wright TA, Greer RO: Estrogen and progesterone receptor and p53 gene expression in adenoid cystic cancer. Head Neck Pathol; 2008 Mar;2(1):13-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen and progesterone receptor and p53 gene expression in adenoid cystic cancer.
  • OBJECTIVES: The current study examined the role of estrogen receptors (ER), progesterone receptors (PR) and p53 expression in adenoid cystic carcinoma (ACC) to determine if simple expression or possible overexpression of these products might influence the development and natural course of this cancer.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Gene Expression Regulation, Neoplastic / physiology. Genes, p53 / physiology. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Salivary Gland Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Oncol. 2001 Apr;37(3):315-22 [11287288.001]
  • [Cites] JAMA. 1968 May 27;204(9):771-4 [4296718.001]
  • [Cites] J Steroid Biochem. 1976 Nov-Dec;7(11-12):923-7 [1025371.001]
  • [Cites] Cancer. 1979 Mar;43(3):980-4 [427738.001]
  • [Cites] Cancer. 1980 Dec 15;46(12 Suppl):2939-45 [7448741.001]
  • [Cites] J Surg Oncol. 1985 Oct;30(2):132-7 [3001428.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1987 Oct;113(10):1082-5 [3620130.001]
  • [Cites] Hum Pathol. 1987 Dec;18(12):1276-81 [2824330.001]
  • [Cites] Cancer. 1989 Jul 1;64(1):196-202 [2731116.001]
  • [Cites] Cell Struct Funct. 1992 Jun;17(3):169-75 [1322800.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1994 Jan;77(1):36-40 [8108094.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Oct;80(4):440-4 [8521108.001]
  • [Cites] Histopathology. 1999 Sep;35(3):241-8 [10469216.001]
  • [Cites] Oncogene. 2007 Feb 26;26(9):1317-23 [17322917.001]
  • [Cites] Oral Oncol. 2000 Sep;36(5):450-3 [10964052.001]
  • (PMID = 20614336.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ PMC2807605
  • [Keywords] NOTNLM ; Adenoid cystic carcinoma / Estrogen and progesterone receptors / p53 gene
  •  go-up   go-down


51. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MJ, Van't Veer LJ, Peterse JL: Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol; 2008 Oct;216(2):141-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refinement of breast cancer classification by molecular characterization of histological special types.
  • Most invasive breast cancers are classified as invasive ductal carcinoma not otherwise specified (IDC NOS), whereas about 25% are defined as histological 'special types'.
  • These special-type breast cancers are categorized into at least 17 discrete pathological entities; however, whether these also constitute discrete molecular entities remains to be determined.
  • Current therapy decision-making is increasingly governed by the molecular classification of breast cancer (luminal, basal-like, HER2+).
  • The molecular classification is derived from mainly IDC NOS and it is unknown whether this classification applies to all histological subtypes.
  • We aimed to refine the breast cancer classification systems by analysing a series of 11 histological special types [invasive lobular carcinoma (ILC), tubular, mucinous A, mucinous B, neuroendocrine, apocrine, IDC with osteoclastic giant cells, micropapillary, adenoid cystic, metaplastic, and medullary carcinoma] using immunohistochemistry and genome-wide gene expression profiling.
  • Hierarchical clustering analysis confirmed that some histological special types constitute discrete entities, such as micropapillary carcinoma, but also revealed that others, including tubular and lobular carcinoma, are very similar at the transcriptome level.
  • When classified by expression profiling, IDC NOS and ILC contain all molecular breast cancer types (ie luminal, basal-like, HER2+), whereas histological special-type cancers, apart from apocrine carcinoma, are homogeneous and only belong to one molecular subtype.
  • Our analysis also revealed that some special types associated with a good prognosis, such as medullary and adenoid cystic carcinomas, display a poor prognosis basal-like transcriptome, providing strong circumstantial evidence that basal-like cancers constitute a heterogeneous group.
  • Taken together, our results imply that the correct classification of breast cancers of special histological type will allow a more accurate prognostication of breast cancer patients and facilitate the identification of optimal therapeutic strategies.
  • [MeSH-major] Breast Neoplasms / classification. Carcinoma, Ductal, Breast / classification. Gene Expression Regulation, Neoplastic


52. Nuwal P, Dixit R, Singhal AK: Primary adenoid cystic carcinoma of trachea presenting as midline neck swelling and mimicking thyroid tumor: A case report and review of literature. Lung India; 2010 Jul;27(3):167-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenoid cystic carcinoma of trachea presenting as midline neck swelling and mimicking thyroid tumor: A case report and review of literature.
  • We report an extremely rare case of primary adenoid cystic carcinoma (ACC) trachea presenting as midline swelling neck and mimicking thyroid tumor.
  • Fine needle aspiration cytology (FNAC) from swelling reveal features of papillary carcinoma thyroid.
  • Subsequently the operative findings, bronchoscopy and histological diagnosis of excised mass, along with review of FNAC, revealed features of ACC of trachea with exra tracheal extension anteriorly into the soft tissue neck, without actual invasion of the thyroid gland.
  • The cytological differential diagnosis of ACC and CT findings are also briefly discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20931039.001).
  • [ISSN] 0974-598X
  • [Journal-full-title] Lung India : official organ of Indian Chest Society
  • [ISO-abbreviation] Lung India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2946722
  • [Keywords] NOTNLM ; Adenoid cystic carcinoma trachea / midline swelling neck / thyroid tumor
  •  go-up   go-down


53. Pino Rivero V, González Palomino A, Pantoja Hernández CG, Marcos García M, Trinidad Ruiz G, Pardo Romero G, Blasco Huelva A: [Sinonasal cystic adenoid carcinoma with epiphora and orbital involvement. Report of a case and review of the literature]. An Otorrinolaringol Ibero Am; 2005;32(3):245-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sinonasal cystic adenoid carcinoma with epiphora and orbital involvement. Report of a case and review of the literature].
  • [Transliterated title] Carcinoma adenoide quístico nasosinusal con epífora y afectación orbitaria. Presentación de un caso y revisión de la literatura.
  • We report the clinical case of a 41 years old male with nasal obstruction of 1 year, epistaxis and epiphora.
  • The biopsy was positive for cystic adenoid carcinoma.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Lacrimal Apparatus Diseases / pathology. Orbital Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001694.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 14
  •  go-up   go-down


54. Ouadnouni Y, Bouchikh M, Jahid A, Achir A, Smahi M, Msougar Y, Lakranbi M, Herrak L, Mahassini N, Benosman A: [Tracheal adenoid cystic carcinoma]. Pan Afr Med J; 2010;7:21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tracheal adenoid cystic carcinoma].
  • [Transliterated title] Carcinome adénoïde kystique tracheal.
  • [MeSH-major] Carcinoma, Adenoid Cystic / surgery. Dyspnea / etiology. Tracheal Neoplasms / surgery

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Breathing Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Presse Med. 2003 Apr 5;32(13 Pt 1):602 [12718319.001]
  • [Cites] Rev Pneumol Clin. 2003 Sep;59(4):197-200 [14699295.001]
  • [Cites] Ann Thorac Surg. 1990 Jan;49(1):69-77 [2153371.001]
  • [Cites] Cancer Radiother. 2005 Nov;9(6-7):358-61 [16168695.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):751-3 [16916400.001]
  • (PMID = 21918708.001).
  • [ISSN] 1937-8688
  • [Journal-full-title] The Pan African medical journal
  • [ISO-abbreviation] Pan Afr Med J
  • [Language] fre
  • [Publication-type] Journal Article
  • [Publication-country] Uganda
  • [Other-IDs] NLM/ PMC3172634
  •  go-up   go-down


55. Pino Rivero V, Pantoja Hernández CG, González Palomino A, Trinidad Ramos G, Pardo Romero G, Marcos García M, Pereda Tamayo JM, Blasco Huelva A: [Adenoid cystic carcinoma of the larynx-hypopharynx. A case report and review of the literature]. An Otorrinolaringol Ibero Am; 2006;33(4):339-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic carcinoma of the larynx-hypopharynx. A case report and review of the literature].
  • [Transliterated title] Carcinoma adenoide quístico de laringe-hipofaringe. A propósito de un caso y revisión de la literatura.
  • Laryngeal or hypopharyngeal localization of adenoid cystic carcinoma is rare due to the poor distribution of the accesory salivary glands in this area.
  • We report one case of such neoplasm on that area, with its diagnosis confirmed histologically.
  • We review the literature of this tumor whose prognosis is much worse than epidermoid or scamous carcinoma.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / surgery. Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / surgery. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / surgery

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910388.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 18
  •  go-up   go-down


56. Teymoortash A, Ramaswamy A, Werner JA: [Adenoid cystic carcinoma secondary to heterotopic salivary gland tissue of the cervical lymph nodes]. Laryngorhinootologie; 2007 Jan;86(1):44-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic carcinoma secondary to heterotopic salivary gland tissue of the cervical lymph nodes].
  • [Transliterated title] Adenoidzystisches Karzinom im heterotopen Speicheldrüsengewebe der zervikalen Lymphknoten.
  • BACKGROUND: The presence of heterotopic salivary gland tissue in intra-, periparotideal and cervical lymph nodes is not an uncommen finding.
  • The histological assessment of the extirpated node seemed to indicate lymph node metastasis of an adenoid cystic carcinoma.
  • RESULTS: Due to the fact of missing of a primary tumor, the diagnosis of an adenoid cystic carcinoma in heterotopic salivary gland tissue of the cervical lymph node was established after long-term observation.
  • CONCLUSION: After exclusion of an occult carcinoma of the salivary glands, the possibility of malignant transformation of heterotopic intranodal salivary gland inclusions should be considered in patients suffering from salivary gland carcinoma in the area of the cervical lymph nodes.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Cell Transformation, Neoplastic / pathology. Choristoma / pathology. Lymph Nodes / pathology. Otorhinolaryngologic Neoplasms / pathology. Salivary Glands
  • [MeSH-minor] Diagnosis, Differential. Humans. Lymph Node Excision. Male. Middle Aged

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16586289.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


57. Ward BK, Seethala RR, Barnes EL, Lai SY: Basal cell adenocarcinoma of a hard palate minor salivary gland: case report and review of the literature. Head Neck Oncol; 2009 Dec 23;1:41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of a hard palate minor salivary gland: case report and review of the literature.
  • OBJECTIVE: Basal cell adenocarcinoma of a minor salivary gland is extremely rare.
  • The goal of this report is to increase awareness of this rare disease and to review and discuss the differential diagnosis and important considerations in treatment.
  • METHODS: Case report of a basal cell adenocarcinoma of a hard palate minor salivary gland and review of the literature of basal cell adenocarcinoma.
  • Histological diagnosis is important to distinguish this tumour from adenoid cystic carcinoma given the significant difference in disease prognosis.
  • CONCLUSIONS: Diagnosis of these tumours must be made histologically.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol. 1978 Feb;104(2):111-6 [629699.001]
  • [Cites] J Oral Pathol. 1985 Jul;14(6):500-9 [2991488.001]
  • [Cites] Arch Pathol Lab Med. 1988 Feb;112(2):209-11 [2827601.001]
  • [Cites] J Laryngol Otol. 1989 Aug;103(8):756-9 [2769045.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Apr;69(4):461-9 [2326038.001]
  • [Cites] Cancer. 1996 Dec 15;78(12):2471-7 [8952553.001]
  • [Cites] Oral Oncol. 2008 Apr;44(4):407-17 [17825603.001]
  • [Cites] HNO. 1998 Sep;46(9):821-5 [9816537.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jul;34(5):528-32 [16053873.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Feb;35(2):150-4 [16181771.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2006 Mar;11(2):E206-9 [16505803.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jan;103(1):77-84 [17178498.001]
  • [Cites] J Oral Pathol Med. 2007 Apr;36(4):207-14 [17391298.001]
  • [Cites] Acta Otolaryngol. 1998 Jul;118(4):588-93 [9726688.001]
  • (PMID = 20030819.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / K08 DE018061
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2806868
  • [General-notes] NLM/ Original DateCompleted: 20100629
  •  go-up   go-down


58. Huang ZQ, Chen WL, Li HG, Li JS, Xu ZY, Lin ZY: Extracellular matrix metalloproteinase inducer expression in salivary gland tumors: a correlation with microvessel density. J Craniofac Surg; 2010 Nov;21(6):1855-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracellular matrix metalloproteinase inducer expression in mucoepidermoid carcinomas and adenoid cystic carcinomas was significantly higher than in normal salivary gland tissues and pleomorphic adenomas (P < 0.05).
  • The MVD of mucoepidermoid carcinomas and adenoid cystic carcinomas was significantly higher compared with pleomorphic adenomas (P < 0.05).
  • [MeSH-minor] Adenoma, Pleomorphic / blood supply. Adenoma, Pleomorphic / immunology. Angiogenesis Inducing Agents / analysis. Antigens, CD34 / analysis. Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / blood supply. Carcinoma, Adenoid Cystic / immunology. Carcinoma, Mucoepidermoid / blood supply. Carcinoma, Mucoepidermoid / immunology. Epithelium / blood supply. Epithelium / immunology. Humans. Immunohistochemistry. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Salivary Ducts / blood supply. Salivary Ducts / immunology. Salivary Glands / blood supply. Salivary Glands / immunology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119439.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Antigens, CD34; 0 / Antigens, Neoplasm; 0 / BSG protein, human; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 136894-56-9 / Antigens, CD147
  •  go-up   go-down


59. Maruyama S, Cheng J, Yamazaki M, Zhou XJ, Zhang ZY, He RG, Saku T: Metastasis-associated genes in oral squamous cell carcinoma and salivary adenoid cystic carcinoma: a differential DNA chip analysis between metastatic and nonmetastatic cell systems. Cancer Genet Cytogenet; 2010 Jan 1;196(1):14-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis-associated genes in oral squamous cell carcinoma and salivary adenoid cystic carcinoma: a differential DNA chip analysis between metastatic and nonmetastatic cell systems.
  • Overall modes of differential gene expressions were analyzed between human oral/salivary carcinoma cell systems with (MK-1 and ACCM) and without (ZK-1/ZK-2 and ACC2/ACC3) metastatic potential by using micro-array analysis with cancer-associated DNA chips to determine the kinds of genes associated with metastatic behaviors.
  • MK-1 and/or ACCM showed lower levels of gene expression in extracellular matrix-related molecules, such as collagen type IV, laminin, and adhesion molecules such as cadherin 2, but higher levels of genes which control extracellular matrix degradation, such as MMP 9, as well as cell growth and cycle, such as FGF7 and cyclin D1.
  • Among the differentially expressed genes, similar protein expression tendencies for FGF7, laminin, cyclin D1, and collagen type IV were confirmed by immunofluorescence.
  • Metastatic potentials of oral/salivary carcinoma cells seem to have resulted from certain combinations of over-/underexpression of the genes, which were responsible for extracellular matrix metabolism and cell growth in particular.
  • [MeSH-major] Carcinoma, Adenoid Cystic / genetics. Carcinoma, Squamous Cell / genetics. Mouth Neoplasms / genetics. Neoplasm Metastasis / genetics. Oligonucleotide Array Sequence Analysis. Salivary Gland Neoplasms / genetics


60. Yamada T, Mouri H, Izumi K, Takeuchi S, Ohtsubo K, Yamashita K, Yasumoto K, Kitamura S, Yano S: [Combined chemotherapy with cisplatin plus vinorelbine showed efficacy in a case of metastatic primary cutaneous adenoid cystic carcinoma]. Gan To Kagaku Ryoho; 2010 Aug;37(8):1545-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined chemotherapy with cisplatin plus vinorelbine showed efficacy in a case of metastatic primary cutaneous adenoid cystic carcinoma].
  • We report a case of a 65-year-old man with metastatic primary cutaneous adenoid cystic carcinoma that was effectively treated by combination chemotherapy with cisplatin (CDDP) plus vinorelbine(VNR).
  • He was given a diagnosis of primary cutaneous adenoid cystic carcinoma with metastatic lesions to multiple lungs and left tibial bone and then given chemotherapy combining CDDP plus VNR as the first treatment in December 2008.
  • We reported the efficacy of combined treatment with CDDP plus VNR for primary cutaneous adenoid cystic carcinoma, because this clinical condition was very rare and the standard treatment has still not been established.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Adenoid Cystic / drug therapy. Cisplatin / therapeutic use. Lung Neoplasms / drug therapy. Skin Neoplasms / drug therapy. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20716883.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


61. Jensen AD, Nikoghosyan A, Windemuth-Kieselbach C, Debus J, Münter MW: Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC. BMC Cancer; 2010 Oct 11;10:546
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High local control rates in adenoid cystic carcinomas could be achieved by highly conformal radiotherapy techniques and particle (neutron/carbon ion) therapy.
  • METHODS/DESIGN: The COSMIC trial is a prospective, mono-centric, phase II trial evaluating toxicity (primary endpoint: mucositis ≥ CTCAE°3) and efficacy (secondary endpoint: local control, disease-free survival) in the combined treatment with IMRT and carbon ion boost in 54 patients with histologically proved (≥R1-resected, inoperable or Pn+) salivary gland malignancies.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Radiother Oncol. 2001 May;59(2):161-7 [11325445.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):391-8 [12738314.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):944-8 [12975266.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):631-40 [14751537.001]
  • [Cites] Head Neck. 2004 Feb;26(2):154-62 [14762884.001]
  • [Cites] Head Neck. 2004 Aug;26(8):681-92; discussion 692-3 [15287035.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):358-64 [15380567.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] Cancer. 1994 May 15;73(10):2563-9 [8174054.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):103-11 [15629600.001]
  • [Cites] Laryngoscope. 2005 Jul;115(7):1278-82 [15995521.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):338-44 [15937907.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):152-9 [16904520.001]
  • [Cites] Radiat Oncol. 2006;1:17 [16756669.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Nov;132(11):1242-9 [17116822.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):982-7 [17241753.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):410-4 [18374509.001]
  • (PMID = 20937120.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT01154270
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ions; 7440-44-0 / Carbon
  • [Other-IDs] NLM/ PMC2958954
  •  go-up   go-down


62. Razak AR, Siu LL, Le Tourneau C: Molecular targeted therapies in all histologies of head and neck cancers: an update. Curr Opin Oncol; 2010 May;22(3):212-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECENT FINDINGS: The use of cetuximab in squamous cell head and neck cancer is associated with clinical benefit and, in some cases, survival.
  • However, the use of targeted agents beyond cetuximab in this disease remains investigational.
  • Combination therapy of molecular targeted agents with chemoradiation in the locally advanced setting of head and neck squamous cell carcinomas and nasopharyngeal cancer shows early promising results, but at the expense of increased toxicity.
  • The recent identification of improved prognosis among head and neck squamous cell carcinoma patients whose tumors harbor the human papilloma virus may allow better treatment selection for these patients, while the identification of a hallmark gene fusion transcript in adenocystic carcinoma may herald new treatment promise.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / therapy. Drug Delivery Systems / methods. Head and Neck Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173639.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; PQX0D8J21J / Cetuximab
  • [Number-of-references] 77
  •  go-up   go-down


63. Jensen AD, Krauss J, Weichert W, Debus J, Münter MW: RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab. Radiat Oncol; 2010;5:102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab.
  • BACKGROUND: Local control in adjuvant/definitive RT of adenoid cystic carcinoma (ACC) is largely dose-dependent.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Carbon Radioisotopes / therapeutic use. Carcinoma, Adenoid Cystic / radiotherapy. Heavy Ions / therapeutic use. Radioimmunotherapy / methods
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Cetuximab. Combined Modality Therapy. Disease-Free Survival. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Intensity-Modulated

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Am J Clin Oncol. 2011 Feb;34(1):76-81 [20177363.001]
  • [Cites] Radiother Oncol. 2001 May;59(2):161-7 [11325445.001]
  • [Cites] Tumori. 2001 Jan-Feb;87(1):14-7 [11669550.001]
  • [Cites] Head Neck. 2002 Jul;24(7):632-6 [12112535.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):944-8 [12975266.001]
  • [Cites] Head Neck. 2004 Feb;26(2):154-62 [14762884.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):358-64 [15380567.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):951-5 [3585449.001]
  • [Cites] Cancer. 1987 Dec 15;60(12):2869-72 [2824016.001]
  • [Cites] Cancer. 1988 Dec 1;62(11):2313-9 [3179947.001]
  • [Cites] Head Neck. 1992 Jul-Aug;14(4):273-7 [1381339.001]
  • [Cites] Cancer. 1994 May 15;73(10):2563-9 [8174054.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1935-40 [10213503.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):103-11 [15629600.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):585-90 [15659505.001]
  • [Cites] Laryngoscope. 2005 Jul;115(7):1278-82 [15995521.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):338-44 [15937907.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Am J Clin Oncol. 2006 Apr;29(2):153-7 [16601434.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):152-9 [16904520.001]
  • [Cites] Radiat Oncol. 2006;1:17 [16756669.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Nov;132(11):1242-9 [17116822.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2696-705 [17121916.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1044-50 [16965870.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):982-7 [17241753.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2191-7 [17538164.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3978-84 [17761983.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1365-72 [18029108.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5518-23 [18936479.001]
  • [Cites] Oral Oncol. 2009 Jul;45(7):574-8 [18804410.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2009 Jul;135(7):687-92 [19620591.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):21-8 [19897418.001]
  • [Cites] Radiother Oncol. 2010 Jun;95(3):308-11 [20385414.001]
  • [Cites] Cancer Biother Radiopharm. 1999 Dec;14(6):451-63 [10850332.001]
  • (PMID = 21047402.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Carbon Radioisotopes; PQX0D8J21J / Cetuximab
  • [Other-IDs] NLM/ PMC2987937
  •  go-up   go-down


64. Lin CH, Yen RF, Jeng YM, Tzen CY, Hsu C, Hong RL: Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate. Head Neck; 2005 Dec;27(12):1022-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate.
  • BACKGROUND: There is a lack of effective treatment for metastatic adenoid cystic carcinoma (ACC), a usually indolent tumor.
  • Mutations of c-kit and platelet-derived growth factor receptor (PDGFR)-alpha in tumors from these patients were analyzed.
  • RESULTS: Disease progression was noted in three of five patients during the short treatment periods, ranging from 2 to 3 weeks.
  • Three patients died of disease within 6 months.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma, Adenoid Cystic / drug therapy. Head and Neck Neoplasms / pathology. Lung Neoplasms / drug therapy. Piperazines / adverse effects. Pyrimidines / adverse effects
  • [MeSH-minor] Administration, Oral. Adult. Benzamides. DNA Mutational Analysis. Disease Progression. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Pilot Projects. Pleural Effusion, Malignant / pathology. Protein-Tyrosine Kinases / antagonists & inhibitors

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc.
  • (PMID = 16265655.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


65. Friedrich RE: Dermal cylindroma of the scalp (turban tumour) and subjacent calvarian defects. Anticancer Res; 2010 May;30(5):1793-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermal cylindroma of the scalp (turban tumour) and subjacent calvarian defects.
  • This case report describes the diagnosis and therapy of a patient with a 40-year history of multiple potato-like tumours growing in the head and neck region.
  • The tumour proved to be a cylindroma, associated with calvarian defects.
  • A long lasting history of cylindroma and evidence for bone destruction, not associated with a malignant transformation, is extremely rare in Brooke-Spiegler's syndrome.
  • [MeSH-major] Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / pathology. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / pathology. Scalp / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Angiography / methods. Biopsy. Carotid Arteries / pathology. Female. Humans. Magnetic Resonance Imaging / methods. Skin / pathology. Syndrome. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592381.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


66. Maruya S, Shirasaki T, Nagaki T, Kakehata S, Kurotaki H, Mizukami H, Shinkawa H: Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications. BMC Cancer; 2009;9:72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications.
  • BACKGROUND: Salivary gland carcinomas are relatively uncommon heterogeneous malignancies characterized by locoregional invasion and distant metastasis.
  • METHODS: The protein expression of topoIIalpha was evaluated immunohistochemically in formalin-fixed, paraffin-embedded tissue from 54 salivary gland carcinomas and 20 benign tumors (10 pleomorphic adenomas and 10 Warthin's tumors).
  • The primary salivary gland carcinoma specimens consisted of 17 adenoid cystic carcinomas, 7 adenocarcinomas not otherwise specified, 7 mucoepidermoid carcinomas, 6 salivary duct carcinomas, 3 acinic cell carcinomas, 3 carcinomas ex pleomorphic adenomas, 3 epithelial-myoepithelial carcinomas, 2 carcinosarcomas, 2 lymphoepithelial carcinomas, 2 myoepithelial carcinomas, 1 oncocytic carcinoma, and 1 squamous cell carcinoma.
  • RESULTS: Of the 54 primary salivary gland carcinomas, 38 (70%) showed positive expression (> or = 10%) of topoIIalpha protein, and 16 carcinomas (30%) and all benign tumors were negative (p < 0.001).
  • Expression of topoIIalpha was more frequently observed in salivary duct carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was associated with advanced stage and shortened survival.
  • Furthermore, it may provide useful prognostic information and suggests the potential efficacy of topoIIalpha-targeting therapy in patients with salivary gland carcinoma.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Salivary Gland Neoplasms / enzymology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / enzymology. Carcinoma, Adenoid Cystic / pathology. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2000 Aug;22(5):489-97 [10897109.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 [12042765.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):235-43 [12067686.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Jan-Feb;65(1):26-32 [12624503.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):715-22 [12760291.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4682-8 [14581337.001]
  • [Cites] Int J Oncol. 2004 Jan;24(1):201-9 [14654958.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3965-70 [14666704.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):944-6 [14871971.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):328-31 [14974865.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):637-45 [15044918.001]
  • [Cites] Arch Otolaryngol. 1984 Mar;110(3):172-6 [6322732.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1062-9 [6088017.001]
  • [Cites] Oncology (Williston Park). 1998 May;12(5):671-80; discussion 683 [9597678.001]
  • [Cites] Pathol Res Pract. 2005;200(11-12):791-9 [15792122.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R374-84 [15987433.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):64-77 [17113234.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):735-41 [17113340.001]
  • [Cites] Head Neck. 2007 Nov;29(11):1002-9 [17427971.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • (PMID = 19250538.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2654461
  •  go-up   go-down


67. Messaoudi C, Larouk R, Baili S, Noui B, Benchaoui M, Benkadri H, Belbekri F: [Adenoid cystic carcinoma of the larynx. A case report and review of the literature]. Rev Laryngol Otol Rhinol (Bord); 2007;128(1-2):97-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic carcinoma of the larynx. A case report and review of the literature].
  • [Transliterated title] Carcinome adénoïde kystique du larynx. Revue de la littérature, à propos d'un cas.
  • Cylindroma of the head and neck, known as "cystic adenoid carcinoma", begins more often at the expense of the all glandular structures of ectodermic origin, in particularly at the minor and principal salivary glands.
  • RESULTS: The patient is free of disease after six months of follow up.
  • CONCLUSION: The laryngeal cylindroma is rare.
  • The symptomatology does not show a proper characteristic, the diagnosis is a histological finding, and the natural evolution is marked by the very show development of this tumour the onset of cervical lymphatic adenopathy.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Laryngeal Neoplasms / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633677.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 33
  •  go-up   go-down


68. Closmann JJ, Schmidt BL: Adenoid cystic carcinoma manifesting as maxillary jaw pain refractory to conventional treatment: a case report. Gen Dent; 2006 May-Jun;54(3):195-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma manifesting as maxillary jaw pain refractory to conventional treatment: a case report.
  • Adenoid cystic carcinoma is an indolent, slow-growing tumor that may first cause low-grade pain in the affected region.
  • This article describes a case involving adenoid cystic carcinoma of the maxilla that was present for approximately nine years.
  • Prior to diagnosis, five dentists reported that the patient had anisocoria, migraine headaches, and low-to-moderate upper jaw pain that was refractory to conventional therapy.
  • [MeSH-major] Carcinoma, Adenoid Cystic / diagnosis. Facial Pain / diagnosis. Maxillary Diseases / diagnosis. Maxillary Neoplasms / diagnosis
  • [MeSH-minor] Adult. Anisocoria / diagnosis. Denture Design. Denture, Partial, Temporary. Diagnosis, Differential. Female. Humans. Migraine Disorders / diagnosis. Palatal Obturators. Prosthesis Design. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16776413.001).
  • [ISSN] 0363-6771
  • [Journal-full-title] General dentistry
  • [ISO-abbreviation] Gen Dent
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Madani I, Bonte K, Vakaet L, Boterberg T, De Neve W: Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys; 2009 Feb 1;73(2):424-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor histologic type was adenocarcinoma in 54, squamous cell carcinoma in 17, esthesioneuroblastoma in 9, and adenoid cystic carcinoma in 4.
  • The 5-year local control, overall survival, disease-specific survival, disease-free survival, and freedom from distant metastasis rate was 70.7%, 58.5%, 67%, 59.3%, and 82.2%, respectively.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Hospitals, University. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18755554.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Hao L, Xiao-lin N, Qi C, Yi-ping Y, Jia-quan L, Yan-ning L: Nerve growth factor and vascular endothelial growth factor: retrospective analysis of 63 patients with salivary adenoid cystic carcinoma. Int J Oral Sci; 2010 Mar;2(1):35-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nerve growth factor and vascular endothelial growth factor: retrospective analysis of 63 patients with salivary adenoid cystic carcinoma.
  • AIM: To detect the expression of nerve growth factor (NGF) and vascular endothelial growth factor (VEGF) in salivary adenoid cystic carcinoma (SACC) tissues, as well as to determine the correlation between growth factor expression and prognosis in SACC.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Nerve Growth Factor / analysis. Salivary Gland Neoplasms / pathology. Vascular Endothelial Growth Factor A / analysis

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20690417.001).
  • [ISSN] 1674-2818
  • [Journal-full-title] International journal of oral science
  • [ISO-abbreviation] Int J Oral Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 9061-61-4 / Nerve Growth Factor
  • [Other-IDs] NLM/ PMC3475596
  •  go-up   go-down


71. Jeong HS, Son YI, Baek CH: The pattern of lymphatic metastasis of malignant tumors in the periorbital area. Am J Otolaryngol; 2006 Jan-Feb;27(1):5-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathological diagnoses were 3 squamous cell carcinomas, 2 adenoid cystic carcinomas, 2 sebaceous carcinomas, and 1 basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / secondary. Carcinoma, Squamous Cell / secondary. Lymph Nodes / pathology. Orbital Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Korea. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360815.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Farrell T, Chang YL: Basal cell adenocarcinoma of minor salivary glands. Arch Pathol Lab Med; 2007 Oct;131(10):1602-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of minor salivary glands.
  • Basal cell adenocarcinoma of minor salivary glands is a relatively rare slow-growing tumor with an infiltrating growth pattern.
  • The infiltrating growth pattern and likelihood of vascular and perineural involvement distinguishes basal cell adenocarcinoma from basal cell adenoma.
  • Other diagnostic considerations include adenoid cystic carcinoma and basaloid squamous carcinoma.
  • It is necessary to differentiate basal cell adenocarcinoma from other basaloid cell tumors of the minor salivary glands because of the prognosis and potential differences in treatment, particularly adenoid cystic adenocarcinoma and basaloid squamous carcinoma.
  • Surgical excision with a wide margin to ensure complete removal has been suggested as the primary treatment for basal cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adenoma / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Squamous Cell / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922602.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Miyamoto J, Tatsuzawa K, Owada K, Kawabe T, Sasajima H, Mineura K: Usefulness and limitations of fluorine-18-fluorodeoxyglucose positron emission tomography for the detection of malignancy of orbital tumors. Neurol Med Chir (Tokyo); 2008;48(11):495-9; discussion 499
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological examination identified 7 lesions as malignant: anaplastic astrocytoma of the optic nerve in 1 patient, which recurred as glioblastoma of the optic nerve, malignant lymphoma of mucosa-associated lymphoid tissue type in 1 patient, malignant melanoma in 1 patient, adenoid cystic carcinoma in 2 patients, and adenocarcinoma (unknown origin) in 1 patient.
  • [18F]FDG PET can determine the malignancy of orbital tumors, but cannot distinguish malignant tumor from inflammatory disease such as pseudotumor.
  • [MeSH-minor] Adenocarcinoma / radionuclide imaging. Adolescent. Adult. Aged. Astrocytoma / radionuclide imaging. Carcinoma, Adenoid Cystic / radionuclide imaging. Diagnosis, Differential. Female. Fluorine Radioisotopes. Fluorodeoxyglucose F18. Glioblastoma / radionuclide imaging. Hemangioma, Cavernous, Central Nervous System / radionuclide imaging. Humans. Lymphoma, B-Cell, Marginal Zone / radionuclide imaging. Male. Melanoma / radionuclide imaging. Middle Aged. Neurilemmoma / radionuclide imaging. Orbital Pseudotumor / radionuclide imaging. Radiopharmaceuticals. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19029776.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


74. Maiuri F, Gangemi M, Giamundo A, Mariniello G, Colella A, Vergara P, Del Basso De Caro ML: Intracranial extension of salivary gland tumors. Clin Neuropathol; 2010 Jan-Feb;29(1):9-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary tumors were an adenocarcinoma and a malignant oncocytoma of the parotid gland and an adenoid cystic carcinoma of the submandibular gland.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Brain Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040327.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


75. Shi H, Wang J, Dong FS, Wang X, Li HX: [Relationship between proteoglycans and proliferation of human salivary adencid cystic carcinoma]. Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 Jan;45(1):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between proteoglycans and proliferation of human salivary adencid cystic carcinoma].
  • OBJECTIVE: To investigate the effect of down-regulated proteoglycans on the proliferation of human salivary adenoid cystic carcinoma (SACC).
  • Adenoid cystic carcinoma cells with high metastatic tendency (ACC-M) were transfected by shRNA-WJ3.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Cell Proliferation. Pentosyltransferases / metabolism. Proteoglycans / metabolism. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20368035.001).
  • [ISSN] 1002-0098
  • [Journal-full-title] Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology
  • [ISO-abbreviation] Zhonghua Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proteoglycans; 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 2.4.2.- / Pentosyltransferases; EC 2.4.2.26 / UDP xylose-protein xylosyltransferase
  •  go-up   go-down


76. Bhandare N, Monroe AT, Morris CG, Bhatti MT, Mendenhall WM: Does altered fractionation influence the risk of radiation-induced optic neuropathy? Int J Radiat Oncol Biol Phys; 2005 Jul 15;62(4):1070-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: Between 1964 and 2000, 273 patients with tumors of the nasopharynx, paranasal sinuses, nasal cavity, and hard palate adenoid cystic carcinomas were treated with curative intent and had radiation fields that included the optic nerves and/or chiasm.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Optic Nerve Disorders.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15990010.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


77. Xie W, Li X, Ren G, Guo W: Expression and importance of inhibitor of DNA binding helix-loop-helix protein in salivary adenoid cystic carcinoma. Br J Oral Maxillofac Surg; 2010 Sep;48(6):434-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and importance of inhibitor of DNA binding helix-loop-helix protein in salivary adenoid cystic carcinoma.
  • Studies have reported that Id-1 (inhibitor of DNA binding, or differentiation 1) protein, helix-loop-helix (HLH) transcription factor, has important roles in the development of several carcinomas.
  • However, the role of Id-1 protein in salivary adenoid cystic carcinoma (ACC) is not clear.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Gene Expression Regulation, Neoplastic. Inhibitor of Differentiation Protein 1 / biosynthesis. Salivary Gland Neoplasms / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19766362.001).
  • [ISSN] 1532-1940
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Inhibitor of Differentiation Protein 1
  •  go-up   go-down


78. Zhang Y, Liu J, Xue F, Li J: p16 tumor suppressor therapy in salivary adenoid cystic carcinoma cell line SACC83. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Jul;100(1):70-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 tumor suppressor therapy in salivary adenoid cystic carcinoma cell line SACC83.
  • OBJECTIVE: This study aimed to determine the growth inhibitory effects of transfecting the wild-type p16 gene into human salivary adenoid cystic carcinoma (SACC) cells in vitro.
  • METHODS: p16 cDNA was cloned into pDOR-neo plasmid by recombination technique, and the human eukaryotic expression vector, pDOR-p16 , was constructed.
  • CONCLUSION: The study confirmed the reversal effect of wild-type p16 on malignant phenotype of the salivary adenoid cystic carcinoma and provides valuable data for further clinical trial of gene therapy with p16.
  • [MeSH-major] Carcinoma, Adenoid Cystic / therapy. Genes, p16 / physiology. Genetic Therapy. Salivary Gland Neoplasms / therapy

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15953919.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue; 9007-49-2 / DNA
  •  go-up   go-down


79. Soysal HG: Orbital exenteration: a 10-year experience of a general oncology hospital. Orbit; 2010 Jun;29(3):135-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital exenteration: a 10-year experience of a general oncology hospital.
  • The age, sex, the location of tumour, the duration of symptoms, histopathological diagnosis, and previous recurrences were noted.
  • Seven different types of histopathology were encountered: squamous cell carcinoma (31 cases), basal cell carcinoma (26 cases), malignant melanoma (5 cases), sebaceous cell carcinoma (2 cases), rhabdomyosarcoma (2 cases), mucoepidermoid carcinoma (1 case) and adenoid cystic carcinoma (1 case).
  • CONCLUSIONS: Large proportion of the patients that underwent exenteration had a history of previous unsuccessful treatment and a long duration of disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20497078.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


80. Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, Casieri P, Orsenigo M, Losa M, Bergamini C, Liberatoscioli C, Quattrone P, Calderone RG, Rinaldi G, Pilotti S, Licitra L: Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol; 2009 Jul;45(7):574-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study.
  • EGFR overexpression in salivary gland carcinomas provides the rational for the investigation of anti-EGFR treatments in recurrent and/or metastatic salivary gland cancers (RMSGCs).
  • The activity of cetuximab in terms of clinical benefit rate (CBR) defined as the occurrence of objective response (CR or PR) or stable disease (SD) for >or=6months was investigated.
  • From April to December 2005, 30 patients [23 adenoid cystic carcinoma (ACC) and 7 non-ACC] were treated with cetuximab at 400mg/m(2)/week followed by 250mg/m(2)/week until progression, major toxicity or voluntary discontinuation.
  • Skin toxicity was the main adverse event.
  • Skin rash >or=G2, EGFR overexpression and EGFR copy number were not statistically correlated to CB.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Adenoid Cystic / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salivary Gland Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Humanized. Cetuximab. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Palliative Care / methods. Receptor, Epidermal Growth Factor / metabolism. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18804410.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


81. Liang S, Fan M: Immunotherapy for adenoid cystic carcinoma of salivary glands: cancer/testis antigens and 5-aza-2'-deoxycytidine. Med Hypotheses; 2009 Nov;73(5):768-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy for adenoid cystic carcinoma of salivary glands: cancer/testis antigens and 5-aza-2'-deoxycytidine.
  • Adenoid cystic carcinoma of salivary glands is the epithelial tumor.
  • There are amount of malignant occurrences of adenoid cystic carcinoma of salivary glands in the head and neck area.
  • Cancer/testis antigens can be found in various malignant tumors, normal adult testis and occasionally placenta, but not in the other normal adult tissues.
  • This characteristic makes Cancer/testis antigens as potential markers to be applied in immunotherapeutic strategies against cancer.
  • It has been shown that in different tumors, the expression of certain Cancer/testis antigens is activated treated with 5-aza-CdR via the demethylation of their promoter CpG islands.
  • It is logical that multiple Cancer/testis antigens may correlate with the clinicopathologic factors of adenoid cystic carcinoma of salivary glands and be the potential markers of prognosis treated with 5-aza-CdR.
  • So the hypothesis will provide the new direction that we can use Cancer/testis antigens as candidate antigens for adenoid cystic carcinoma of salivary glands immunotherapy due to the high expression rate activated with 5-aza-CdR.
  • [MeSH-major] Antigens, Neoplasm / immunology. Carcinoma, Adenoid Cystic / therapy. Immunotherapy. Salivary Gland Neoplasms / therapy. Testis / immunology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19481355.001).
  • [ISSN] 1532-2777
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  •  go-up   go-down


82. Jaeger RG, Scarabotto-Neto N, Azambuja N Jr, Freitas VM: Secretion of collagen I and tenascin is modulated by laminin-111 in 3D culture of human adenoid cystic carcinoma cells. Int J Exp Pathol; 2008 Apr;89(2):98-105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretion of collagen I and tenascin is modulated by laminin-111 in 3D culture of human adenoid cystic carcinoma cells.
  • Adenoid cystic carcinoma is a frequent malignant salivary gland neoplasm with high levels of recurrence and metastasis.
  • We are studying regulatory mechanisms underlying secretion of ECM molecules in adenoid cystic carcinoma.
  • We have previously demonstrated that laminin modulates the phenotype of a human adenoid cystic carcinoma (CAC2) cell line.
  • We suggest that laminin-111 modulates secretion of collagen I and tenascin in cells derived from human adenoid cystic carcinoma.
  • [MeSH-major] Carcinoma, Adenoid Cystic / secretion. Collagen Type I / secretion. Laminin / pharmacology. Neoplasm Proteins / secretion. Tenascin / secretion

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Matrix Biol. 2000 Dec;19(7):581-96 [11102748.001]
  • [Cites] Oral Oncol. 2007 Nov;43(10):987-98 [17257887.001]
  • [Cites] Oral Oncol. 2001 Dec;37(8):638-42 [11590073.001]
  • [Cites] Virchows Arch. 2001 Oct;439(4):571-8 [11710645.001]
  • [Cites] Virchows Arch. 2002 Dec;441(6):569-76 [12461614.001]
  • [Cites] J Oral Pathol Med. 2003 May;32(5):290-6 [12694353.001]
  • [Cites] Oral Oncol. 2004 Jan;40(1):36-42 [14662413.001]
  • [Cites] Oral Oncol. 2004 May;40(5):483-9 [15006619.001]
  • [Cites] Hum Pathol. 1983 Sep;14(9):780-97 [6309645.001]
  • [Cites] Hum Pathol. 1983 Sep;14(9):798-809 [6309646.001]
  • [Cites] Oral Oncol. 2000 Mar;36(2):248-52 [10745180.001]
  • [Cites] Dev Dyn. 2000 Jun;218(2):235-59 [10842355.001]
  • [Cites] Histopathology. 2000 Aug;37(2):118-23 [10931234.001]
  • [Cites] J Oral Pathol. 1986 Jul;15(6):308-18 [2428959.001]
  • [Cites] Cancer. 1992 Jun 1;69(11):2631-40 [1315206.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;420(5):425-31 [1375797.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):379-85 [1617588.001]
  • [Cites] Experientia. 1995 Mar 15;51(3):194-5 [7698270.001]
  • [Cites] Virchows Arch. 1995;426(6):577-86 [7655738.001]
  • [Cites] Curr Biol. 1996 Jun 1;6(6):645-7 [8793283.001]
  • [Cites] J Cell Biol. 1997 Apr 7;137(1):231-45 [9105051.001]
  • [Cites] Cancer Lett. 1997 Jun 3;116(1):9-14 [9177451.001]
  • [Cites] Virchows Arch. 1997 Jun;430(6):467-77 [9230912.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Dec;84(6):663-7 [9431536.001]
  • [Cites] Int J Biochem Cell Biol. 2005 May;37(5):1066-83 [15743679.001]
  • [Cites] J Cell Sci. 2005 Apr 1;118(Pt 7):1341-53 [15788652.001]
  • [Cites] Matrix Biol. 2005 Aug;24(5):326-32 [15979864.001]
  • [Cites] Cancer Lett. 2006 Dec 8;244(2):143-63 [16632194.001]
  • [Cites] Matrix Biol. 2007 Apr;26(3):146-55 [17141492.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):124-38 [17591960.001]
  • [Cites] Matrix Biol. 2001 Sep;20(5-6):337-45 [11566268.001]
  • (PMID = 18336527.001).
  • [ISSN] 1365-2613
  • [Journal-full-title] International journal of experimental pathology
  • [ISO-abbreviation] Int J Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / Gels; 0 / Laminin; 0 / Neoplasm Proteins; 0 / Tenascin; 0 / laminin 1
  • [Other-IDs] NLM/ PMC2525767
  •  go-up   go-down


83. Elhassani LK, Mrabti H, Ismaili N, Bensouda Y, Masbah O, Bekkouch I, Hassouni K, Kettani F, Errihani H: Advanced adenoid cystic carcinoma of the cervix: a case report and review of the literature. Cases J; 2009;2:6634
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced adenoid cystic carcinoma of the cervix: a case report and review of the literature.
  • INTRODUCTION: Adenoid cystic carcinoma is a malignant epithelial neoplasm derived from the salivary glands.
  • Primary adenoid cystic carcinoma of the cervix is extremely rare, accounting for less than 1% of all cervical carcinomas.
  • In this paper we report a case of primary adenoid cystic carcinoma and a review of the related literature.
  • CASE PRESENTATION: A 68 year-old woman was admitted with signs and symptoms suggestive of a cervical cancer.
  • The radiological and pathological investigations confirmed the diagnostic of primary adenoid cystic carcinoma of the cervix at Stage IIIB according to the International Federation of Gynaecology and Obstetrics classification.
  • CONCLUSION: The optimal management of adenoid cystic carcinoma cannot be established for certain.
  • Concurrent chemo-radiotherapy appears to be a logical option for locally advanced disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1949 Jul;58(1):184-7 [18151180.001]
  • [Cites] Obstet Gynecol. 1971 Jul;38(1):103-10 [4327155.001]
  • [Cites] Int J Clin Oncol. 2005 Jun;10(3):198-200 [15990970.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):448-58 [10199475.001]
  • [Cites] J Postgrad Med. 1994 Apr-Jun;40(2):94-5 [8737564.001]
  • [Cites] Obstet Gynecol. 1995 May;85(5 Pt 2):903-5 [7724157.001]
  • [Cites] J Postgrad Med. 1993 Oct-Dec;39(4):211-5 [7996499.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):352-7 [2227547.001]
  • [Cites] Obstet Gynecol. 1985 May;65(5):705-9 [2580256.001]
  • [Cites] Gynecol Oncol. 1985 Oct;22(2):260-2 [2996997.001]
  • [Cites] Gynecol Oncol. 1985 Oct;22(2):201-11 [2996994.001]
  • [Cites] Gynecol Oncol. 1985 Oct;22(2):167-73 [2996993.001]
  • [Cites] Gynecol Oncol. 1989 Jan;32(1):26-30 [2909445.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1631-5 [6251966.001]
  • [Cites] Am J Obstet Gynecol. 1981 Apr 1;139(7):799-814 [7211986.001]
  • [Cites] Gynecol Oncol. 1979 Jun;7(3):371-84 [221309.001]
  • [Cites] Obstet Gynecol. 1978 Sep;52(3):337-42 [212702.001]
  • [Cites] Cancer. 1971 Jun;27(6):1398-402 [4325985.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):477-80 [16139349.001]
  • (PMID = 19829837.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2740204
  •  go-up   go-down


84. Qi ZZ, Shang DH, Qu CF, Sun CF: [The expression of M-phase promoting factor in salivary adenoid cystic carcinoma]. Shanghai Kou Qiang Yi Xue; 2007 Jun;16(3):243-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression of M-phase promoting factor in salivary adenoid cystic carcinoma].
  • PURPOSE: To study the expression and clinical significance of M-phase promoting factor (MPF) in salivary adenoid cystic carcinoma (SACC).
  • METHODS: The expression of MPF was investigated in 40 salivary adenoid cystic carcinomas and 40 normal salivary tissues by immunohistochemistry.
  • RESULTS: The expression of MPF was significantly higher in salivary adenoid cystic carcinoma than in normal salivary tissues(P<0.05).
  • There was significant correlation between the level of MPF expression and pathological type(P<0.05).
  • CONCLUSIONS: MPF highly expressed in salivary adenoid cystic carcinoma, salivary adenoid cystic carcinoma correlated with the expression of MPF and the abnormal activation of MPF was one of the factors for the proliferation of salivary adenoid cystic carcinoma.
  • Metastasis in salivary adenoid cystic carcinoma correlated with the expression of MPF.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Maturation-Promoting Factor / metabolism. Salivary Gland Neoplasms / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660907.001).
  • [ISSN] 1006-7248
  • [Journal-full-title] Shanghai kou qiang yi xue = Shanghai journal of stomatology
  • [ISO-abbreviation] Shanghai Kou Qiang Yi Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.11.22 / Maturation-Promoting Factor
  •  go-up   go-down


85. Dodd RL, Slevin NJ: Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol; 2006 Sep;42(8):759-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies.
  • Adenoid cystic carcinoma (ACC) accounts for about 1% of all head and neck malignancies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Adenoid Cystic / drug therapy. Salivary Gland Neoplasms / drug therapy


86. Li J, El-Naggar A, Mao L: Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. Cancer; 2005 Aug 15;104(4):771-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma.
  • However, little is known about its role in the development of adenoid cystic carcinoma of the salivary gland (ACC).
  • [MeSH-major] Carcinoma, Adenoid Cystic / genetics. Genes, Tumor Suppressor. Methylation. Promoter Regions, Genetic. Salivary Gland Neoplasms / genetics

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15959912.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA106451
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  •  go-up   go-down


87. Li Z, Cen Y, Yang K: [Modified transcranial approach to resect tumor around the anterior skull base and double tissue flap to reconstruct the anterior skull base]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2006 Sep;20(9):896-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In November 2004, a 49-years-old male patient with intracranial recrudescent adenoid cystic carcinoma in the anterior cranial fossa was treated using modified transcranial approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17036975.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


88. Bi YW, Chen RJ: [Clinical and pathological analysis of 151 cases of tumors in lacrimal fossa]. Zhonghua Yan Ke Za Zhi; 2005 Oct;41(10):877-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In 69 cases of benign lacrimal epithelial tumors, pleomorphic adenoma was the most common tumor (63 cases, 41.7%), followed by myoepithelioma (3 cases, 1.2%), lacrimal duct cyst (2 cases, 1.3%).
  • In 34 cases of malignant lacrimal epithelial tumors, adenoid cystic carcinoma was the most common tumor (15 cases, 9.9%), followed by pleomorphic adenocarcinoma (14 cases, 9.3%), adenocarcinoma (4 cases, 2.6%).
  • The treatment of pleomorphic adenoma and the diagnosis of MALT lymphoma are the most difficult tasks in present clinical work.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Lacrimal Apparatus Diseases / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Orbital Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16271170.001).
  • [ISSN] 0412-4081
  • [Journal-full-title] [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  • [ISO-abbreviation] Zhonghua Yan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


89. Hentschel SJ, Vora Y, Suki D, Hanna EY, DeMonte F: Malignant tumors of the anterolateral skull base. Neurosurgery; 2010 Jan;66(1):102-12; discussion 112
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most frequently occurring pathologies after the various sarcomas were squamous cell carcinoma (SCC) and adenoid cystic carcinoma (ACC) in 23% and 14% of patients, respectively.


90. Korkontzelos I, Fragkoulidis M, Stavroulis A, Apostolikas N, Terzakis E: Adenoid cystic carcinoma of the Bartholin's gland in a young patient: eight-year follow-up. Eur J Gynaecol Oncol; 2009;30(6):686-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the Bartholin's gland in a young patient: eight-year follow-up.
  • Adenoid cystic carcinoma (ACC) of the Bartholin's gland is one of the rarest neoplasms of the female genital tract.
  • We report a case of a 36-year-old woman who presented at our hospital after excision of the right Bartholin gland elsewhere which proved to be ACC.
  • Our patient underwent surgical treatment only (hemivulvectomy and lymph node dissection) without radiotherapy and is free of disease eight years after.
  • [MeSH-major] Bartholin's Glands / pathology. Carcinoma, Adenoid Cystic / pathology. Vulvar Neoplasms / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20099506.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


91. Mastropasqua MG, Maiorano E, Pruneri G, Orvieto E, Mazzarol G, Vento AR, Viale G: Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. Mod Pathol; 2005 Oct;18(10):1277-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast.
  • Adenoid cystic carcinoma of the breast represents a unique clinicopathologic entity with a variable histological appearance and a relatively indolent clinical course in most of the cases.
  • Adenoid cystic carcinoma may be difficult to differentiate from infiltrating duct carcinomas, and in particular from tubular and cribriform carcinomas, especially in core or vacuum-assisted biopsies.
  • We evaluated the prevalence of c-kit, p63, and e-cadherin immunoreactivity in a series of 20 adenoid cystic carcinomas, comparing the results with those obtained in a series of infiltrating tubular carcinomas and infiltrating cribriform carcinomas.
  • Three (15%) adenoid cystic carcinomas and all infiltrating tubular and cribriform carcinomas showed estrogen receptor and/or progesterone receptor immunoreactivity (P < 0.00001 for estrogen and P = 0.00002 for progesterone receptors).
  • Adenoid cystic carcinomas consistently lacked any immunoreactivity for HER/2, whereas three (15%) infiltrating and cribriform carcinomas showed weak and incomplete membrane staining (P = 0.23077).
  • Membranous immunoreactivity for c-kit was found in all except one (predominantly basaloid) adenoid cystic carcinomas (95%), and in none of the infiltrating tubular and cribriform carcinomas (P < 0.00001).
  • Nuclear immunoreactivity for p63 was found in all except three (predominantly basaloid) adenoid cystic carcinomas (85%) and in none of the infiltrating tubular and cribriform carcinomas (P < 0.00001).
  • All infiltrating tubular and cribriform carcinomas and 18/20 (90%) adenoid cystic carcinomas showed immunoreactivity for e-cadherin (P = 0.48718).
  • In summary, adenoid cystic carcinomas showed the following phenotype: estrogen receptor-/progesterone receptor-/c-kit+/p63+ (13 cases, 65%), estrogen receptor-/progesterone receptor/c-kit+/p63- (three cases, 15%), estrogen receptor-/progesterone receptor-/c-kit-/p63+ (one case, 5%), estrogen receptor+/progesterone receptor+/c-kit+/p63+ (two cases, 10%), and estrogen receptor+/progesterone receptor-/c-kit+/p63+ (one case).
  • By contrast, all the infiltrating tubular and cribriform carcinomas showed the estrogen receptor+/progesterone receptor+/c-kit-/p63- phenotype.
  • Our data provide evidence that immunoreactivity for c-kit and/or p63 may be useful in differentiating adenoid cystic carcinomas from other types of breast cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Adenoid Cystic / metabolism. Membrane Proteins / metabolism. Proto-Oncogene Proteins c-kit / metabolism


92. Al-Khateeb TH, Ababneh KT: Salivary tumors in north Jordanians: a descriptive study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 May;103(5):e53-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumors were analyzed for age of patient, sex of patient, tumor site, and tumor type.
  • The most frequent benign and malignant neoplasms found were pleomorphic adenoma (54%) and adenoid cystic carcinoma (13%), respectively.
  • Although most of major gland tumors were adenomas, carcinomas of the minor glands were only slightly less frequent than adenomas.
  • The most frequent malignant parotid tumors were adenoid cystic carcinoma and mucoepidermoid carcinoma.
  • The most frequent minor salivary gland malignant tumors were palatal adenoid cystic carcinoma.
  • CONCLUSION: North Jordanians with salivary gland tumors were found to have similar characteristics with patients of other countries with regard to tumor type, tumor site distribution, and age and sex of patients.
  • [MeSH-major] Adenoma, Pleomorphic / epidemiology. Carcinoma, Adenoid Cystic / epidemiology. Salivary Gland Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17368055.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Adamski H, Le Lan J, Chevrier S, Cribier B, Watier E, Chevrant-Breton J: Primary cutaneous cribriform carcinoma: a rare apocrine tumour. J Cutan Pathol; 2005 Sep;32(8):577-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous cribriform carcinoma: a rare apocrine tumour.
  • BACKGROUND: Primary cutaneous cribriform carcinoma (PCCC) is a rare apocrine tumour occurring in middle-aged people.
  • The histopathological diagnosis is difficult, mainly because this tumour is exceptional.
  • Differential diagnoses, including cutaneous metastasis of adenocarcinoma, adenoid basal cell carcinoma and adenoid cystic carcinoma, are discussed.
  • [MeSH-major] Adenocarcinoma / pathology. Apocrine Glands / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115058.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


94. Benchetritt M, Butori C, Long E, Ilie M, Ferrari E, Hofman P: Pericardial effusion as primary manifestation of metastatic cutaneous adenoid cystic carcinoma: diagnostic cytopathology from an exfoliative sample. Diagn Cytopathol; 2008 May;36(5):351-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pericardial effusion as primary manifestation of metastatic cutaneous adenoid cystic carcinoma: diagnostic cytopathology from an exfoliative sample.
  • Adenoid cystic carcinoma (ACC) occurs not only as a tumor of salivary glands, but also in very unusual locations, such as in the skin.
  • [MeSH-major] Carcinoma, Adenoid Cystic / secondary. Heart Neoplasms / secondary. Pericardial Effusion / pathology. Pericardium / pathology. Skin Neoplasms / pathology


95. Wang L, Sun M, Jiang Y, Yang L, Lei D, Lu C, Zhao Y, Zhang P, Yang Y, Li J: Nerve growth factor and tyrosine kinase A in human salivary adenoid cystic carcinoma: expression patterns and effects on in vitro invasive behavior. J Oral Maxillofac Surg; 2006 Apr;64(4):636-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nerve growth factor and tyrosine kinase A in human salivary adenoid cystic carcinoma: expression patterns and effects on in vitro invasive behavior.
  • PURPOSE: Perineural invasion is a frequent occurrence in salivary adenoid cystic carcinoma (ACC) and may prevent complete surgical resection.
  • The present study was conducted to investigate the expression of NGF and TrkA in salivary ACC and to examine the effects of NGF on adhesion, migration and invasion capacities of a salivary ACC cell line (SACC-83) in vitro.
  • [MeSH-major] Carcinoma, Adenoid Cystic / secondary. Nerve Growth Factor / biosynthesis. Peripheral Nervous System Neoplasms / secondary. Receptor, trkA / biosynthesis. Salivary Gland Neoplasms / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546643.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9061-61-4 / Nerve Growth Factor; EC 2.7.10.1 / Receptor, trkA
  •  go-up   go-down


96. Yamazaki M, Fujii S, Murata Y, Hayashi R, Ochiai A: High expression level of geminin predicts a poor clinical outcome in salivary gland carcinomas. Histopathology; 2010 Jun;56(7):883-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression level of geminin predicts a poor clinical outcome in salivary gland carcinomas.
  • AIMS: To examine the prognostic impact of geminin expression, a negative regulator of DNA replication, in salivary gland carcinomas.
  • METHODS AND RESULTS: Tissues from 170 patients with salivary gland carcinoma were assembled in a tissue microarray format, and immunohistochemistry staining for geminin and Ki67 was performed.
  • Patients were categorized into three groups using the tertile values of the labelling index (LI) for each marker as the cut-off points for constructing Kaplan-Meier survival curves.
  • The LI for geminin was relatively low in acinic cell carcinoma (mean 1.55%) and mucoepidermoid carcinoma (mean 2.43%), intermediate in adenoid cystic carcinoma (mean 4.09%), and relatively high in salivary duct carcinoma (mean 15.22%).
  • CONCLUSIONS: Geminin expression is potentially a useful marker for predicting tumour aggressiveness and clinical outcome in salivary gland carcinomas.
  • [MeSH-major] Carcinoma / metabolism. Carcinoma / mortality. Cell Cycle Proteins / metabolism. Salivary Gland Neoplasms / metabolism. Salivary Gland Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20497246.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / GMNN protein, human; 0 / Geminin; 0 / Ki-67 Antigen
  •  go-up   go-down


97. Gaissert HA, Mark EJ: Tracheobronchial gland tumors. Cancer Control; 2006 Oct;13(4):286-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bronchial gland tumors demonstrate oncologic diversity and include benign, low-grade, and high-grade malignant tumors.
  • METHODS: We reviewed the present knowledge of bronchial gland tumors of the trachea, carina, and bronchi, including the epidemiology, presentation, evaluation, tumor types, and treatment options.
  • RESULTS: The malignant bronchial gland tumors, adenoid cystic carcinoma and mucoepidermoid carcinoma, are far more common than benign mucinous cystadenoma or pleomorphic adenoma.
  • The disease-free survival after resection of malignant tumors is limited by distant metastasis and regional disease, while local recurrence is uncommon.
  • [MeSH-major] Bronchial Neoplasms. Neoplasms, Glandular and Epithelial. Tracheal Neoplasms

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075566.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  •  go-up   go-down


98. Kara MI, Göze F, Ezirganli S, Polat S, Muderris S, Elagoz S: Neoplasms of the salivary glands in a Turkish adult population. Med Oral Patol Oral Cir Bucal; 2010 Nov;15(6):e880-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: The histological diagnosis records of the Department of Pathology at Cumhuriyet University were reevaluated for 125 patients who were treated for salivary gland tumors from 1987 to 2008.
  • The neoplasms were analyzed for histological diagnosis, age, sex, and site.
  • Pleomorphic adenoma was the most frequent benign tumor followed by Warthin's tumor.
  • Among the malignant group, adenoid cystic carcinoma was the most prevalent.
  • CONCLUSIONS: Although there were some discrepancies, the characteristics of salivary gland tumors of Turkish patients are in line with those of patients from other countries according to tumor type, tumor site distribution, and age and sex of patients.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20526249.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


99. Ahn Y, Chang H, Lim YS, Hah JH, Kwon TK, Sung MW, Kim KH: Primary tracheal tumors: review of 37 cases. J Thorac Oncol; 2009 May;4(5):635-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Except the papilloma cases (n = 3), all of them were managed successfully without recurrence.
  • Squamous cell carcinomas (n = 11) and adenoid cystic carcinomas (n = 9) comprised most of the malignant tumors.
  • Five-year overall survival rate was 41.1% for squamous cell carcinoma and 45.7% for adenoid cystic carcinoma and no statistically significant difference (p = 0.673) was observed.
  • Among malignant tumors, surgery should be considered as the first choice of treatment, regardless of the histologic type, if the tumors are resectable.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Carcinoma, Squamous Cell / pathology. Papilloma / pathology. Tracheal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19357541.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Adachi M, Iwai H, Yagi M, Minamino M, Omae M, Lee S, Yamashita T: [Clinical study of adenoid cystic carcinoma of the parotid gland]. Nihon Jibiinkoka Gakkai Kaiho; 2007 May;110(5):410-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of adenoid cystic carcinoma of the parotid gland].
  • We report results of a retrospective study of 12 cases of adenoid cystic carcinoma (ACC) in the parotid gland.
  • Although fine-needle aspiration cytology (FNA) was not effective for preoperative diagnosis, frozen section diagnosis (FS) during surgery showed excellent results.
  • Postoperative radiation therapy seemed useful in these cases and the 5-and 10-year disease-specific survivals in these 12 cases were 90.0% and 80.8%.
  • [MeSH-major] Carcinoma, Adenoid Cystic / therapy. Parotid Neoplasms / therapy

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17564131.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement